Real-Time Caspase Activity Monitoring in 3D Organoids: A Guide for Advanced Drug Discovery and Disease Modeling

Abstract

This article provides a comprehensive resource for researchers and drug development professionals on monitoring caspase activity in 3D organoid models. It covers the foundational principles of regulated cell death and the superiority of 3D systems over traditional 2D cultures. The piece details cutting-edge methodological approaches, including fluorescent biosensors and high-content imaging, for real-time, single-cell tracking of apoptosis in complex organoids. It further offers practical troubleshooting and optimization strategies to enhance reproducibility and scalability. Finally, it explores the validation of these models against clinical outcomes and their application in personalized medicine, highlighting how caspase activity data can guide therapeutic decisions and improve the predictive power of preclinical studies.

Why 3D Organoids? Unveiling the Critical Role of Caspase Monitoring in Physiologically Relevant Models

The study of apoptosis, or programmed cell death, is fundamental to biomedical research, with implications spanning from developmental biology to cancer therapy. For decades, traditional two-dimensional (2D) cell cultures have served as the primary platform for caspase activity monitoring and apoptosis assessment. However, these monolayer models suffer from significant limitations as they fail to recapitulate the complex three-dimensional (3D) architecture, cell-cell interactions, and physiological microenvironments found in living tissues [1]. The emergence of 3D organoid technology represents a transformative advancement in apoptosis research, offering self-organizing, multicellular structures derived from stem cells that closely mimic the complexity of human organs [2] [3]. This application note examines the limitations of traditional 2D apoptosis assays and details the sophisticated methodologies required for accurate caspase activity monitoring within 3D organoid models, providing researchers with comprehensive protocols for this cutting-edge approach.

The Limitations of Traditional 2D Apoptosis Assays

Traditional 2D apoptosis assays, while well-established and straightforward to implement, present critical limitations that can compromise their physiological relevance and predictive value. The table below summarizes the key constraints of 2D systems compared to the advantages offered by 3D organoid models.

Table 1: Limitations of Traditional 2D Apoptosis Assays vs. Advantages of 3D Organoids

Aspect	Traditional 2D Models	3D Organoid Models
Physiological Context	Lack tissue architecture and cell-cell interactions [1]	Recapitulate organ-specific structure and cellular organization [2] [3]
Drug Penetration	Uniform, non-physiological drug distribution [1]	Physiologically relevant gradient formation [1]
Microenvironment	Absence of extracellular matrix (ECM) and mechanical cues [3]	Native-like ECM with biophysical and biochemical signaling [3]
Cellular Responses	Altered polarity, signaling, and gene expression [1]	In vivo-like gene expression and functional responses [1] [3]
Predictive Value for Drug Efficacy	Poor correlation with human clinical outcomes [1]	High correlation with patient-specific drug responses [1] [4]
Heterogeneity	Limited cellular diversity [4]	Representation of complex cellular populations [4] [3]

The constraints of 2D systems are particularly problematic in drug development, where the artificial microenvironment can dramatically alter cellular responses to therapeutic compounds. For instance, apoptosis pathways activated in 2D cultures may not correspond to those triggered in more physiologically relevant 3D contexts, potentially explaining the high failure rate of compounds that show promise in conventional 2D screening [1]. Furthermore, the lack of proper tissue architecture in 2D models prevents the study of spatially regulated apoptotic processes, such as the differential responses of cells in hypoxic cores versus perfused regions, which are critical phenomena in tumor biology [4].

3D Organoids: A Physiologically Relevant Model System

Organoids are 3D multicellular microtissues derived from stem cells or tissue-specific progenitors that self-organize to replicate the structural, genetic, and functional characteristics of human organs [2] [3]. These models offer unprecedented advantages for apoptosis research and drug evaluation by bridging the gap between traditional 2D cultures and in vivo physiology. Organoids can be generated from various tissue sources, including pluripotent stem cells (PSCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and patient-derived tumor samples, enabling researchers to model organ-specific apoptosis in both developmental and disease contexts [3].

The enhanced biological relevance of organoids stems from their ability to recreate critical aspects of native tissue microenvironments, including:

• Complex architecture: Organoids develop organ-specific spatial organization with appropriate cell polarity and lumen formation [2]
• Cellular heterogeneity: They contain multiple cell types found in the corresponding native tissue [4] [3]
• Cell-ECM interactions: Organoids are typically cultured in biomimetic extracellular matrices like Matrigel that provide structural support and biochemical signaling [3]
• Self-organization: They recapitulate developmental processes and tissue patterning through autonomous cellular assembly [3]

These characteristics make organoids particularly valuable for studying context-dependent apoptotic responses in disease modeling and therapeutic screening. For example, tumor organoids derived from cancer patients have demonstrated remarkable ability to predict individual responses to chemotherapy and targeted therapies, providing a powerful platform for personalized medicine approaches [4]. The preservation of tumor microenvironment elements in co-culture models further enhances their utility for investigating immunotherapies and their apoptotic mechanisms [4].

Technical Challenges in Apoptosis Detection in 3D Organoids

While organoids offer superior physiological relevance, their 3D architecture presents significant technical challenges for apoptosis monitoring that are not encountered in 2D systems. The key obstacles include:

Reagent Penetration and Diffusion Barriers

The dense, compact structure of organoids impedes uniform penetration of caspase detection reagents and antibodies. Thicker spheroids may require optimized permeabilization strategies and extended incubation times to ensure adequate reagent penetration to the core region [5]. Antibody titration is essential, as too much or too little primary antibody can result in suboptimal labeling, with thicker spheroids often requiring higher antibody concentrations [5].

Imaging and Light Penetration Limitations

3D cultures may be too thick for light to effectively pass through, complicating high-resolution imaging [5]. This limitation necessitates specialized imaging approaches such as confocal microscopy with water immersion objectives to capture the complexity of 3D biological assays [2]. Clearing reagents are strongly recommended when imaging fixed 3D cell cultures to enable optimal clarity for sharp, bright fluorescent images [5].

Image Analysis Complexity

The analysis of 3D datasets presents substantial computational challenges. Conventional 2D analysis tools are insufficient for extracting meaningful quantitative data from 3D structures. Advanced image analysis software capable of 3D reconstruction and quantification is required to assess caspase activity throughout the entire organoid volume [2] [6]. Recent advancements in AI-based segmentation pipelines, such as the 3DCellScope platform, have begun to address these challenges by enabling multi-level segmentation and cellular topology analysis in 3D organoids [6].

Variability and Standardization Issues

Organoid cultures exhibit striking heterogeneity and variable complexity in their cellular composition, which can complicate reproducible apoptosis quantification [3]. This heterogeneity necessitates robust normalization strategies and larger sample sizes to achieve statistical significance. Automated imaging and analysis systems are increasingly important for increasing throughput and standardization of organoid-based assays [2] [6].

Detailed Protocol: Caspase 3/7 Apoptosis Assay in 3D Organoids

The following protocol provides a detailed methodology for detecting caspase 3/7 activity in 3D organoid cultures, incorporating optimized procedures to address the unique challenges of 3D systems.

Table 2: Essential Research Reagents for Organoid Apoptosis Assay

Reagent/Category	Specific Examples	Function/Purpose
Caspase Detection	CellEvent Caspase-3/7 Green or Red Detection Reagent [5]	Target-specific activation by caspase 3/7 in apoptotic cells
Viability Stain	NucBlue Live ReadyProbes Reagent (Hoechst 33342) [5]	Nuclear counterstain for all cells
Fixation Reagent	4% paraformaldehyde (e.g., Image-iT Fixative Solution) [5]	Tissue preservation and structural maintenance
Permeabilization Buffer	CytoVista Antibody Penetration Buffer [5]	Enhances reagent penetration through tissue
Extracellular Matrix	Matrigel [3]	3D structural support for organoid growth
Blocking Buffer	CytoVista Blocking Buffer [5]	Reduces non-specific antibody binding
Mounting Medium	SlowFade Glass Soft-set Antifade Mountant [5]	Preserves fluorescence during imaging
Clearing Reagents	CytoVista 3D Cell Culture Clearing/Staining Kit [5]	Enhances light penetration for imaging

Protocol Workflow: Caspase 3/7 Detection in 3D Organoids

Step-by-Step Procedure

Organoid Culture and Treatment

• Culture organoids in appropriate extracellular matrix (e.g., Matrigel) in 96-well plates suitable for imaging [5].
• Treat organoids with experimental compounds or apoptotic inducers for desired duration. Include appropriate controls (untreated, positive apoptosis control).

Caspase 3/7 Staining (Live Cell Assay)

• Prepare staining solution by diluting CellEvent Caspase-3/7 detection reagent to 2μM and adding 1 drop of NucBlue per milliliter of PBS [5].
• Remove culture media and add staining solution to organoids.
• Incubate for 2 hours at room temperature with gentle agitation, protected from light [5].
• Wash samples 3 times with PBS, centrifuging at 500g for 5 minutes between washes [5].

Fixation and Permeabilization

• Fix organoids with 4% paraformaldehyde for 1 hour at room temperature [5].
• Permeabilize with appropriate penetration buffer (e.g., CytoVista Antibody Penetration Buffer) for 15 minutes at room temperature with gentle agitation [5].
• Wash samples twice with 1% fetal bovine serum in PBS.

Optional Immunostaining (if required)

• Block samples with blocking buffer for 2 hours at 37°C with gentle agitation [5].
• Incubate with primary antibodies diluted in antibody dilution buffer overnight at room temperature [5].
• Wash 3 times with wash buffer.
• Incubate with secondary antibodies prepared in antibody dilution buffer overnight at room temperature [5].
• Wash 3 times with wash buffer.

Mounting and Imaging

• Pipette organoids onto coverslips or use glass-bottom plates.
• Add 1-3 drops of SlowFade Glass Soft-set Antifade Mountant [5].
• Image using a confocal microscope with Z-stack capabilities (e.g., ImageXpress Confocal HT.ai system, EVOS M7000) [2] [5].
• Acquire Z-stacks with appropriate step sizes to resolve entire organoid volume.

Critical Considerations for Protocol Success

• Tip Modification: Cut pipet tips to widen openings to prevent shearing of spheroids during fluid handling [5].
• Antibody Titration: Optimize primary antibody concentrations before use with serial dilutions (1:10, 1:100, 1:500, 1:1000). Thicker spheroids may require more antibody [5].
• Penetration Optimization: For organoids >200μm, consider extended permeabilization times or specialized clearing reagents to enhance reagent penetration [5].
• Viability Integration: For simultaneous viability assessment, consider using fixable LIVE/DEAD dyes before fixation according to manufacturer's protocols [5].

Advanced Imaging and Analysis Solutions for 3D Apoptosis Quantification

Accurate quantification of apoptosis in 3D organoids requires specialized imaging and computational approaches that address the challenges of 3D data analysis.

Imaging System Requirements

For optimal 3D organoid imaging, systems should include:

• Confocal capability: Essential for optical sectioning of 3D samples [2]
• Water immersion objectives: Improve light collection efficiency and resolution for 3D samples [2]
• Z-stack functionality: Enables capture of complete organoid volume [5]
• High-content screening capability: Automated systems like the ImageXpress Confocal HT.ai or CellInsight CX7 platforms enable higher throughput analysis [2] [5]

3D Image Analysis Workflow

Advanced Analysis Approaches

Modern 3D organoid analysis leverages artificial intelligence and specialized software tools to extract meaningful quantitative data:

• AI-Based Segmentation: Platforms like 3DCellScope use convolutional neural networks (DeepStar3D) for precise nuclei segmentation in 3D space, followed by watershed algorithms for whole-cell segmentation using actin signals [6].
• Multi-Scale Quantification: Advanced pipelines enable analysis at nuclear, cytoplasmic, and whole-organoid scales, providing comprehensive morphological signatures [6].
• Spatial Analysis: Tools for evaluating the spatial distribution of apoptotic cells within organoids, including distance to surface, clustering patterns, and correlation with hypoxic regions [6].
• High-Content Descriptors: Automated systems can quantify numerous parameters including organoid volume, shape, intensity of specific markers, and counts of apoptotic cells within each organoid [2].

These advanced analytical approaches enable researchers to move beyond simple apoptotic counts to more sophisticated analyses of spatial patterning and heterogeneity in apoptotic responses within 3D tissue contexts.

Applications in Drug Development and Disease Modeling

The integration of 3D organoid platforms with advanced apoptosis detection methodologies has enabled significant advancements in several research areas:

Drug Screening and Toxicity Assessment

Organoids provide a superior platform for preclinical drug evaluation, offering human-specific drug responses and enabling personalized disease modeling [1]. The preserved tissue architecture allows for more physiologically relevant assessment of drug penetration, toxicity, and efficacy compared to 2D models. Hepatic, cardiac, and neural organoids have been particularly valuable for assessing organ-specific toxicity and drug metabolism [1].

Tumor Biology and Immunotherapy Development

Tumor organoids co-cultured with immune cells have emerged as powerful tools for investigating tumor-immune interactions and immunotherapeutic mechanisms [4]. These co-culture systems enable researchers to observe how immune cells influence tumor growth and apoptosis, and to evaluate the cytotoxic efficacy of tumor-reactive T cells against matched tumor organoids [4]. This approach provides a methodology to assess the sensitivity of tumor cells to T cell-mediated attacks at an individualized patient level.

Personalized Medicine

Patient-derived organoids enable drug screens and toxicity evaluations tailored to individual patients, making significant advancements in personalized medicine [2]. From 2017 to 2023, 42 clinical trials have used tumor organoids derived from cancer patients to aid in optimizing clinical decision-making [3]. These approaches allow for evaluating apoptotic responses to various therapies in patient-specific models before treatment initiation.

The transition from traditional 2D apoptosis assays to 3D organoid models represents a fundamental advancement in our ability to study programmed cell death in physiologically relevant contexts. While this transition presents technical challenges in imaging, analysis, and standardization, the development of sophisticated protocols for caspase detection in 3D systems, coupled with advanced imaging platforms and AI-driven analytical tools, has enabled researchers to overcome many of these obstacles. The integration of 3D organoid technology into apoptosis research and drug screening pipelines promises to enhance the predictive accuracy of preclinical studies and accelerate the development of more effective therapeutics. As organoid technology continues to evolve through innovations in vascularization, immune co-culture, and multi-organ systems, its impact on apoptosis research and personalized medicine will undoubtedly expand, offering unprecedented insights into cell death mechanisms across diverse physiological and pathological contexts.

Apoptosis, or programmed cell death, is a fundamental biological process essential for maintaining tissue homeostasis, eliminating damaged cells, and ensuring proper embryonic development. At the heart of the apoptotic machinery are caspases, a family of cysteine-aspartic proteases that act as central mediators of cell death. Among these, caspase-3 and caspase-7 stand out as the key executioner caspases responsible for the proteolytic cleavage of numerous cellular substrates, leading to the systematic and orderly dismantling of the cell [7] [8]. These executioner caspases are activated by both the intrinsic (mitochondrial) and extrinsic (death receptor) pathways of apoptosis, serving as the critical convergence point where apoptotic signals amplify and become irreversible [9] [10].

The activation of caspase-3/7 represents a commitment to cell death, often described as the "point of no return" in the apoptotic cascade. Upon activation, these enzymes cleave over 600 cellular targets, including structural proteins such as actin and nuclear proteins like PARP and lamin, resulting in the characteristic morphological changes of apoptosis, including cell shrinkage, chromatin condensation, DNA fragmentation, and formation of apoptotic bodies [7] [9]. The detection and quantification of caspase-3/7 activity therefore provides a reliable and specific biomarker for identifying apoptotic cells and assessing the efficacy of therapeutic agents designed to modulate cell death pathways, particularly in cancer research and drug development [11] [12].

Quantitative Profiling of Caspase-3/7 Activity and Specificity

Caspase Cleavage Specificity and Kinetics

Understanding the substrate specificity of various caspases is crucial for developing accurate detection assays. The following table summarizes the cleavage preferences of major caspases, with caspase-3 and -7 showing strong preference for the DEVD sequence.

Table 1: Caspase Specificity for DEVD Cleavage Motif [12]

Caspase	Cleaves DEVD	Preferred Motif	Function / Role
Caspase-3	+++	DEVD	Executioner (apoptosis)
Caspase-7	+++	DEVD	Executioner (apoptosis)
Caspase-6	++	VQVD, VEVD	Executioner (apoptosis)
Caspase-8	++	LETD, XEXD	Initiator (extrinsic pathway)
Caspase-9	+	LEHD, WEHD	Initiator (intrinsic pathway)
Caspase-1	-	WEHD, YVHD	Inflammatory (IL-1β activation)
Caspase-4/5	-	LEVD, WEHD-like	Inflammatory (LPS sensing)
Caspase-14	-	VEHD, VSQD/HSED	Skin differentiation

Experimental Parameters for Caspase-3/7 Detection in 3D Models

The following table outlines key parameters for detecting caspase activity across different experimental models, highlighting the advantages of real-time imaging in 3D cultures.

Table 2: Experimental Caspase-3/7 Detection Data in 2D vs 3D Models [11] [13] [12]

Parameter	Traditional Luminescent Assay (3D)	ZipGFP Reporter (2D Culture)	ZipGFP Reporter (3D Spheroid/Organoid)
Detection Method	Luminescence (Caspase-Glo 3/7)	Fluorescence (ZipGFP)	Fluorescence (ZipGFP)
Readout Type	Endpoint, bulk population	Real-time, single-cell	Real-time, single-cell resolution in 3D structure
Temporal Resolution	Single time point	Continuous monitoring over 80-120 hours	Continuous monitoring over 80-120 hours
Signal Kinetics	N/A	Signal peaks ~24-48h post-induction	Signal appears ~24h, peaks ~72-96h
Key Reagents	Caspase-Glo 3/7 reagent	Carfilzomib, Oxaliplatin, zVAD-FMK	Carfilzomib, Cultrex embedding matrix
Inhibition Control	N/A	>90% inhibition with zVAD-FMK	>90% inhibition with zVAD-FMK
Compatibility	High-throughput screening (Z'=0.67)	Live-cell imaging, multiplexing with other probes	Live-cell imaging in complex 3D environments

Diagram 1: Apoptotic signaling pathways converging on caspase-3/7 activation. Both intrinsic and extrinsic pathways activate executioner caspases that cleave cellular substrates like PARP, leading to apoptotic cell death.

Advanced Methodologies for Caspase-3/7 Monitoring in 3D Organoid Models

Protocol 1: Real-Time Caspase-3/7 Monitoring with ZipGFP Reporter in 3D Organoids

The ZipGFP-based reporter system represents a cutting-edge approach for dynamic, single-cell resolution monitoring of caspase-3/7 activation in physiologically relevant 3D models [11] [12].

Materials and Reagent Setup

• Stable Reporter Cell Lines: Lentiviral-transduced cells expressing ZipGFP-caspase-3/7 reporter with constitutive mCherry marker
• 3D Culture Matrix: Cultrex Basement Membrane Extract or Geltrex matrix
• Culture Vessels: Nunclon Sphera 96-well U-bottom plates for spheroid formation
• Apoptosis Inducers: Carfilzomib (1-10 µM) or Oxaliplatin (10-100 µM)
• Caspase Inhibitor Control: zVAD-FMK (20-50 µM)
• Imaging Equipment: IncuCyte or similar live-cell imaging system with environmental control

Step-by-Step Procedure

• 3D Organoid Generation:

  • Harvest ZipGFP reporter cells at 80-90% confluence using standard trypsinization
  • Resuspend cells in complete growth medium at 1-5 × 10^4 cells/mL concentration
  • Mix cell suspension with Cultrex matrix at 1:1 ratio (final matrix concentration ~2-4 mg/mL)
  • Plate 50 µL mixture per well in 96-well Nunclon Sphera plates
  • Centrifuge plates at 300 × g for 3 minutes to ensure even distribution
  • Incubate at 37°C for 30 minutes to allow matrix polymerization
  • Carefully overlay with 100 µL complete growth medium per well

• Experimental Treatment:

  • Culture organoids for 3-5 days until compact spheroids form (150-300 µm diameter)
  • Pre-treat control wells with 50 µM zVAD-FMK for 2 hours prior to apoptosis induction
  • Add carfilzomib (5 µM final concentration) or vehicle control (DMSO) to appropriate wells
  • Return plates to 37°C incubator with 5% CO₂

• Real-Time Imaging and Data Acquisition:

  • Place culture plate in live-cell imaging system maintained at 37°C with 5% CO₂
  • Program automated image acquisition every 4-6 hours for 96-120 hours
  • Capture both brightfield and fluorescence images (GFP: 488 nm ex/510 nm em; mCherry: 587 nm ex/610 nm em)
  • Use 10× objective for entire spheroid visualization or 20× for single-cell resolution

• Image and Data Analysis:

  • Quantify GFP fluorescence intensity normalized to mCherry signal using integrated analysis software
  • Calculate percentage of GFP-positive cells within organoids over time
  • Generate kinetic curves of caspase activation for different treatment conditions
  • Perform statistical analysis comparing treatment groups to controls (n≥3, p<0.05)

Protocol 2: Multiplexed Endpoint Analysis of Caspase Activity and Immunogenic Cell Death

This protocol enables correlative assessment of caspase activation with immunogenic cell death markers, providing comprehensive profiling of cell death mechanisms [11] [12].

Procedure

• Sample Preparation and Treatment:

  • Generate 3D organoids as described in Protocol 1, steps 1-2
  • Treat with apoptotic inducers for 24-48 hours based on kinetic data from real-time imaging
  • Include controls: untreated, vehicle control (DMSO), and zVAD-FMK pre-treated

• Simultaneous Caspase Activity and Calreticulin Detection:

  • Harvest organoids by gentle mechanical dissociation or enzymatic digestion (TrypLE for 5-10 minutes at 37°C)
  • Wash cells with ice-cold PBS containing 2% FBS
  • Aliquot cells for parallel analyses:
    • Flow cytometry for calreticulin exposure: Stain with anti-calreticulin primary antibody (1:100) for 30 minutes on ice, followed by fluorescent secondary antibody
    • Annexin V/PI staining: Follow manufacturer's protocol to distinguish apoptotic stages
    • Caspase activity measurement: Process samples using Caspase-Glo 3/7 assay according to manufacturer instructions

• Data Integration and Analysis:

  • Analyze flow cytometry data to quantify percentage of calreticulin-positive cells
  • Correlate calreticulin exposure with caspase activity levels and Annexin V/PI staining patterns
  • Perform Western blot analysis on parallel samples for cleaved PARP and cleaved caspase-3 to validate reporter activity

Diagram 2: Integrated workflow for monitoring caspase-3/7 dynamics and secondary phenotypes in 3D organoid models, combining real-time imaging with endpoint assays.

The Scientist's Toolkit: Essential Research Reagents and Solutions

Table 3: Key Research Reagents for Caspase-3/7 Monitoring in 3D Models

Reagent/Assay	Specific Function	Application Notes
ZipGFP Caspase-3/7 Reporter	Caspase-activatable biosensor based on split-GFP with DEVD cleavage motif	Minimal background, irreversible signal upon activation; ideal for long-term imaging [11] [12]
Caspase-Glo 3/7 3D Assay	Luminescent assay for quantitative caspase-3/7 measurement in 3D models	Homogeneous add-mix-measure protocol; compatible with high-throughput screening [13]
Nunclon Sphera Plates	Low-attachment surface with U-bottom for controlled spheroid formation	Enables consistent organoid size and shape; optimized for imaging [14]
Cultrex/Geltrex Matrix	Basement membrane extract for 3D culture support	Physiologically relevant environment; promotes organoid formation and polarity [11] [14]
Carfilzomib	Proteasome inhibitor; robust apoptosis inducer	Positive control for caspase activation; working concentration 1-10 µM [11] [12]
zVAD-FMK	Pan-caspase inhibitor; specificity control	Confirms caspase-dependent signal; use at 20-50 µM for pre-treatment [11] [12] [15]
CytoVista Clearing Reagent	Enables deep imaging within 3D structures	Reduces light scattering; allows visualization of internal caspase activity [14]

Technical Considerations and Advanced Applications

Optimization Strategies for 3D Caspase Imaging

Successful monitoring of caspase dynamics in 3D organoids requires careful optimization of several parameters. Organoid size represents a critical factor, as structures exceeding 300 µm in diameter frequently develop necrotic cores that complicate interpretation of caspase activation patterns [14]. Initial cell seeding density should be titrated to generate organoids of 150-250 µm diameter, which optimally balance physiological relevance with imaging feasibility. For deeper resolution within larger organoids, optical clearing agents such as CytoVista can significantly enhance signal detection from internal regions by reducing light scattering, though these typically require endpoint fixation [14].

The temporal dynamics of caspase activation vary substantially between 2D and 3D culture models. While 2D monolayers typically exhibit peak caspase-3/7 activity within 24-48 hours post-treatment, 3D organoids often demonstrate delayed activation kinetics with signal peaks occurring at 72-96 hours, necessitating extended imaging protocols [11] [12]. This delayed response likely reflects reduced drug penetration and altered cell signaling within the 3D architecture. Researchers should therefore conduct preliminary kinetic studies to establish appropriate imaging windows for specific organoid models and treatment conditions.

Multiplexing with Secondary Phenotypic Assays

The true power of caspase-3/7 monitoring lies in its integration with complementary assays that capture additional dimensions of cell death biology. Apoptosis-induced proliferation (AIP) represents a functionally significant phenomenon wherein apoptotic cells actively stimulate proliferation of neighboring surviving cells through paracrine signaling [11]. This compensatory mechanism can be detected by combining the ZipGFP caspase reporter with proliferation tracking dyes, enabling direct correlation of caspase activation with subsequent proliferation events in adjacent cells.

Similarly, immunogenic cell death (ICD) represents a therapeutically relevant process wherein apoptosis transitions from immunologically silent to actively stimulatory of adaptive immune responses [11] [12]. A defining feature of ICD is the pre-apoptotic exposure of calreticulin on the cell surface, which serves as a potent "eat me" signal for dendritic cells and macrophages. The ZipGFP reporter platform readily accommodates endpoint quantification of surface calreticulin by flow cytometry, facilitating identification of treatment regimens that simultaneously induce caspase activation and immunogenic signaling—a combination with particular relevance for cancer immunotherapy development.

Emerging Research Applications

Recent investigations have revealed unexpectedly diverse functions of executioner caspases that extend beyond traditional intracellular apoptotic roles. Studies now demonstrate that during secondary necrosis—a process occurring when apoptotic cells are not efficiently cleared by phagocytosis—active caspases-3 and -7 can be released into the extracellular space [15]. Once extracellular, these enzymes remain proteolytically active and capable of cleaving extracellular domains of membrane-bound proteins on neighboring cells, potentially influencing cell-cell communication and tumor microenvironment remodeling.

This extracellular caspase activity may be particularly significant in tumor contexts following chemotherapeutic treatment, where impaired clearance mechanisms lead to secondary necrosis and caspase release [15]. The slightly acidic pH characteristic of tumor microenvironments does not abolish extracellular caspase activity, suggesting potential relevance for in vivo signaling. These findings expand the potential biomarker applications of caspase detection beyond simple apoptosis quantification to include assessment of tumor microenvironment modulation and immunogenic signaling.

Tumor heterogeneity and the tumor microenvironment (TME) are critical determinants of cancer progression, therapeutic resistance, and clinical outcomes. Traditional two-dimensional (2D) cell cultures and patient-derived xenograft (PDX) models have limitations in replicating this complexity, often failing to predict clinical responses accurately [16] [17] [18]. Organoid technology has emerged as a transformative approach, enabling the generation of three-dimensional (3D) models that preserve the histological features, cellular diversity, gene expression, and mutational profiles of original tumors [16] [17]. This article explores how patient-derived tumor organoids bridge the gap between traditional models and human cancers, with a specific focus on techniques for monitoring caspase activity as a key metric of treatment response in 3D cultures.

Recapitulating Tumor Heterogeneity in Organoid Models

Preservation of Inter- and Intra-tumoral Heterogeneity

Patient-derived organoids (PDOs) maintain both inter- and intra-tumoral heterogeneity through advanced culture techniques that avoid clonal selection. Unlike traditional methods that dissociate tumors into single cells, leading to selection for highly proliferative subpopulations, newer culture approaches preserve native cytoarchitecture and cell-cell interactions [16]. For instance, glioblastoma organoids (GBOs) established without added EGF/bFGF or extracellular matrix demonstrated retention of original tumor heterogeneity at single-cell resolution, even after long-term culture (24 weeks) [16].

Advanced molecular analyses confirm that PDOs faithfully conserve the genetic and transcriptomic diversity of parent tumors. Bulk RNA sequencing and exome sequencing of organoid biobanks have shown conservation of patient-specific mutational profiles, including single-nucleotide variants, copy number alterations, and structural variants [16] [19]. Single-cell RNA sequencing has further validated the maintenance of cellular subpopulations and their evolution during culture, providing unprecedented insights into tumor dynamics [16].

Quantitative Assessment of Heterogeneity

Technologies like single-cell optical metabolic imaging (OMI) enable the quantification of metabolic heterogeneity within organoid populations. Studies analyzing 2,096 individual PDOs across cancer types revealed wide variations in growth rates (ranging from +20.6% to +201.7%) and metabolic profiles, reflecting the intrinsic diversity of original tumors [19]. This heterogeneity significantly impacts drug responses, with individual organoids within the same culture showing divergent sensitivity to chemotherapeutic agents like FOLFOX [19].

Table 1: Methods for Assessing Tumor Heterogeneity in Organoid Models

Method	Parameters Measured	Application in Organoids
Single-cell RNA sequencing	Cell-type heterogeneity, transcriptional profiles	Identification of cellular subpopulations and their evolution during culture [16]
Bulk exome sequencing	Mutational profiles, copy number variations	Verification of conservation of patient-specific mutations [16] [19]
Optical metabolic imaging (OMI)	NAD(P)H and FAD fluorescence lifetimes, optical redox ratio	Quantification of metabolic heterogeneity and treatment response at single-organoid level [19]
High-content imaging	Organoid size, morphology, viability markers	Analysis of growth heterogeneity and differential drug responses [20] [19]
Fluorescence Lifetime Imaging Redox Ratio (FLIRR)	Cellular metabolism independent of concentration	Comparison of metabolic states across different experimental days [19]

Modeling the Tumor Microenvironment

Strategies for Recapitulating the TME

Various culture strategies have been developed to model the complex tumor ecosystem in organoids:

• Reconstitution approaches: Immune cells, cancer-associated fibroblasts (CAFs), or other stromal components are added to submerged Matrigel cultures [21]. This method allows controlled introduction of specific cell types but may not fully replicate native cellular interactions.

• Holistic approaches: Techniques like air-liquid interface (ALI) culture maintain diverse immune cells and stromal fibroblasts from the original tissue without dissociation [21]. ALI cultures preserve native TME components, including T cells, macrophages, and stromal cells, providing a more physiologically relevant model.

• Microfluidic 3D cultures: These systems enable real-time modeling of tumor-immune interactions with minimal cell numbers and reagent volumes [21]. Though requiring specialized equipment, they offer superior control over microenvironmental conditions.

Immune Microenvironment Modeling

Co-culture systems combining tumor organoids with immune cells have emerged as powerful tools for immuno-oncology research. Peripheral blood lymphocytes co-cultured with tumor organoids can enrich tumor-reactive T cells and assess their cytotoxic efficacy against matched tumor organoids [4]. Similarly, pancreatic cancer organoids co-cultured with peripheral blood mononuclear cells (PBMCs) demonstrate activation of cancer-associated fibroblasts and tumor-dependent lymphocyte infiltration, replicating key aspects of tumor-immune interactions [4].

Caspase Activity Monitoring in 3D Organoid Models

Real-Time Caspase Imaging in Organoids

Monitoring caspase activation provides crucial insights into treatment-induced apoptosis in organoid models. Recent advances in live-cell imaging enable real-time tracking of caspase dynamics in 3D cultures. Fluorescent reporter systems utilizing DEVD-based biosensors can visualize caspase-3/-7 activity at single-cell resolution within complex organoid structures [11].

The ZipGFP-based caspase-3/-7 reporter represents a significant technological advancement. This system features a split-GFP architecture with a caspase-cleavable DEVD motif. Upon caspase activation, the separated GFP fragments reassemble, generating a fluorescent signal that permanently marks apoptotic cells [11]. This system has been successfully applied to patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids, enabling dynamic tracking of apoptotic events following treatment with chemotherapeutic agents [11].

Integrated Cell Death Assessment

Advanced reporter systems now allow simultaneous monitoring of multiple cell death parameters. Beyond caspase activation, these platforms can detect:

• Apoptosis-induced proliferation (AIP): Compensatory proliferation in neighboring cells following apoptotic injury, tracked using proliferation dyes [11].
• Immunogenic cell death (ICD): Measured via surface exposure of calreticulin, a key damage-associated molecular pattern [11].
• Viability metrics: Constitutively expressed fluorescent proteins (e.g., mCherry) enable normalization and viability assessment [11].

Table 2: Caspase Activity Monitoring Methods in 3D Organoid Models

Method	Principle	Applications in Organoids	Advantages	Limitations
ZipGFP caspase reporter [11]	Split-GFP with DEVD cleavage motif	Real-time apoptosis tracking in PDAC organoids, endothelial spheroids	Low background, irreversible signal, single-cell resolution	Requires genetic modification
Caspase-Glo 3/7 3D Assay [13]	Luminescent caspase-3/7 substrate cleavage	Homogeneous apoptosis assessment in 3D models	Simple add-mix-measure protocol, compatible with high-throughput screening	Endpoint measurement only, no single-cell resolution
Multiplexed viability/caspase assays [20]	Combined fluorescent indicators for viability and apoptosis	High-content screening of drug responses	Provides integrated response profiles, accounts for heterogeneous responses	Requires specialized imaging equipment
Annexin V/PI staining with 3D imaging [11]	Phosphatidylserine exposure and membrane integrity	Validation of apoptosis induction in organoids	Widely established, multiple validation studies	Poor penetration in dense organoids, endpoint analysis

Experimental Protocols

Protocol 1: Real-Time Caspase Activity Monitoring in Tumor Organoids

Principle: Utilize stable reporter cell lines expressing caspase-3/7-sensitive biosensor for live imaging of treatment responses [11].

Materials:

• Tumor organoids expressing ZipGFP caspase-3/7 reporter and constitutive mCherry
• 96-well black-walled imaging plates
• Matrigel or other ECM matrix
• Organoid culture medium
• Therapeutic compounds for testing
• Live-cell imaging system with environmental control
• Image analysis software (e.g., IncuCyte AI Cell Health Module)

Procedure:

• Organoid Preparation: Seed caspase reporter-expressing organoids in Matrigel domes in 96-well plates at optimal density (typically 10-50 organoids/well).
• Treatment Application: After 24-48 hours of recovery, add therapeutic compounds at desired concentrations. Include DMSO vehicle controls and positive controls (e.g., 1-10μM carfilzomib).
• Image Acquisition: Place plates in live-cell imaging system maintained at 37°C with 5% CO₂. Acquire GFP (caspase activity) and mCherry (cell presence) images every 4-6 hours for duration of experiment (typically 72-120 hours).
• Image Analysis:
  • Quantify GFP and mCherry fluorescence intensity per organoid
  • Calculate GFP/mCherry ratio to normalize for organoid size and viability
  • Apply algorithms to count caspase-positive organoids and quantify signal intensity
• Data Interpretation:
  • Time to caspase activation: Duration until significant GFP signal increase
  • Maximum response intensity: Peak GFP/mCherry ratio
  • Response heterogeneity: Variation in timing and intensity across organoid population

Protocol 2: High-Content Drug Screening with Multiplexed Apoptosis Readouts

Principle: Combine caspase activity assessment with viability metrics for comprehensive drug response profiling [20].

Materials:

• Patient-derived tumor organoids
• 384-well ultra-low attachment plates
• Caspase-Glo 3/7 3D Assay system [13]
• CellTiter-Glo 3D viability assay
• Automated liquid handling system
• Plate reader capable of luminescence detection
• High-content imaging system (optional)

Procedure:

• Organoid Distribution: Transfer organoids to 384-well plates at optimized density (typically 5-20 organoids/well in 50μL medium).
• Compound Treatment: Add drug library compounds using automated liquid handler. Include controls on each plate.
• Endpoint Assaying:
  • After treatment period (typically 72-96 hours), add 25μL Caspase-Glo 3/7 3D reagent to each well
  • Mix thoroughly, incubate for 30-60 minutes at room temperature
  • Record luminescence (caspase activity)
  • Add 25μL CellTiter-Glo 3D reagent to same wells
  • Mix, incubate 30 minutes, record luminescence (viability)
• Data Analysis:
  • Normalize luminescence values to controls
  • Calculate caspase activation fold-change and viability inhibition
  • Generate dose-response curves for both parameters
  • Determine IC₅₀ values for viability and EC₅₀ for caspase activation

Research Reagent Solutions

Table 3: Essential Reagents for Organoid-based Apoptosis Research

Reagent/Category	Specific Examples	Function/Application	Considerations for 3D Models
Caspase Activity Assays	Caspase-Glo 3/7 3D Assay [13]	Luminescent measurement of caspase-3/7 activity in 3D cultures	Optimized for 3D penetration, compatible with high-throughput screening
Live-Cell Caspase Reporters	ZipGFP-DEVD-mCherry construct [11]	Real-time visualization of caspase activation at single-cell level	Enables longitudinal studies, reveals response heterogeneity
Viability Assays	CellTiter-Glo 3D	ATP-based viability measurement in 3D structures	Modified for improved penetration into organoid cores
Extracellular Matrices	Matrigel, Cultrex, synthetic hydrogels	Provide 3D structural support for organoid growth	Matrix composition affects drug penetration and organoid morphology
Apoptosis Inducers	Carfilzomib, oxaliplatin, navitoclax [11] [22]	Positive controls for caspase activation experiments	Concentration and timing must be optimized for each organoid type
Caspase Inhibitors	zVAD-FMK, specific caspase inhibitors [11]	Specificity controls for caspase-dependent apoptosis	Confirm penetration into 3D structures for effective inhibition

Signaling Pathways and Workflow Diagrams

Experimental Workflow for Caspase Monitoring in Tumor Organoids

Caspase Activation Pathway in Treatment Response

Patient-derived tumor organoids represent a significant advancement in cancer modeling, effectively bridging the gap between traditional preclinical models and human cancers. By preserving tumor heterogeneity and enabling reconstruction of the tumor microenvironment, organoids provide physiologically relevant platforms for drug development and personalized medicine. Integrated caspase activity monitoring in these 3D systems offers dynamic, quantitative assessment of treatment responses, capturing the heterogeneity that often underlies therapeutic resistance. As organoid technology continues to evolve with improvements in vascularization, immune component integration, and standardized protocols, it promises to enhance preclinical prediction of clinical efficacy and accelerate the development of novel cancer therapeutics.

Within the context of 3D organoid culture research, understanding the specific role of caspase activation is paramount, as it directs cell fate along one of several critical pathways. Caspases are evolutionarily conserved cysteine proteases that cleave substrates at specific aspartic acid residues, serving as master regulators of programmed cell death (PCD) and beyond [23]. Traditionally viewed simply as executioners of apoptotic cell death, caspases are now recognized to have multifaceted roles, including the initiation of immunogenic cell death (ICD) and the paradoxical stimulation of cellular repopulation through apoptosis-induced proliferation (AiP) [11] [24]. In 3D organoid models, which more accurately recapitulate in vivo physiology, the dynamics of these caspase-driven processes have profound implications for developmental biology, tissue regeneration, and cancer therapy response. This application note delineates the experimental frameworks for monitoring and distinguishing these interconnected modalities, providing researchers with robust protocols to decipher complex cell death signaling in physiologically relevant systems.

Molecular Mechanisms and Signaling Pathways

The transition from caspase activation to a specific cell death or survival modality is governed by complex molecular interactions within defined signaling pathways. The table below summarizes the key caspases involved and their primary functions across different cell death modalities:

Table 1: Caspase Functions in Different Cell Death Modalities

Caspase	Primary Classification	Key Functions in Cell Death	Specific Substrates/Effectors
Caspase-8	Initiator (DED-containing)	Extrinsic apoptosis, molecular switch for pyroptosis/necroptosis [23]	Cleaves Bid, GSDMC, inhibits necroptosis [23]
Caspase-9	Initiator (CARD-containing)	Intrinsic apoptosis [23]	Forms apoptosome, activates Caspase-3/7 [23]
Caspase-3/7	Effector/Executioner	Execution of apoptosis, induces pyroptosis via GSDME cleavage [23]	Cleaves PARP, lamin, GSDME [23] [11]
Caspase-1	Inflammatory (CARD-containing)	Pyroptosis via inflammasome activation [23] [25]	Cleaves pro-IL-1β, pro-IL-18, GSDMD [23]
Caspase-4/5/11	Inflammatory	Non-canonical pyroptosis [23] [25]	Directly cleaves GSDMD [23]

The following diagram illustrates the central role of caspases in determining cell fate, bridging the pathways of Apoptosis, Immunogenic Cell Death, and Apoptosis-Induced Proliferation.

The decision between these pathways is influenced by the cellular context, including the intensity and duration of caspase activation, the specific caspases involved, and the surrounding microenvironment [26] [24]. In Apoptosis, initiator caspases (-8, -9) activate executioner caspases (-3, -7), leading to controlled cellular dismantling [23]. However, the same executioner caspases can, under specific conditions such as chemotherapy, trigger the emission of Damage-Associated Molecular Patterns (DAMPs) like surface-exposed calreticulin (ecto-CRT) and released HMGB1, thereby converting the process into Immunogenic Cell Death (ICD) [27] [28]. Furthermore, active caspases in dying cells can secrete mitogenic signals like prostaglandin E2 (PGE2), driving Apoptosis-Induced Proliferation (AiP) and tissue repopulation [24].

Quantitative Profiling of Cell Death Modalities

Differentiating between cell death modalities requires monitoring a combination of specific molecular markers and functional assays. The following table provides a comparative profile of key characteristics, informed by current research findings.

Table 2: Quantitative and Qualitative Profiling of Cell Death Modalities

Parameter	Apoptosis	Immunogenic Cell Death (ICD)	Apoptosis-Induced Proliferation (AiP)
Caspase-3/7 Activity	High, sustained activation [11]	High, sustained activation [11] [28]	Present (required for signaling) [24]
Key Hallmarks	PS externalization, PARP cleavage, nuclear condensation [23] [29]	Ecto-CRT, released HMGB1 & ATP [27] [28]	Secretion of mitogens (e.g., PGE2, Wnt) [24]
Membrane Integrity	Maintained (until late stages) [29]	Lost (lytic), or maintained prior to lysis [27]	Maintained in signaling cells [26]
Inflammatory/Immune Response	Anti-inflammatory, silent clearance [29]	Pro-inflammatory, activates adaptive immunity [27]	Non-autonomous proliferation, can be pro-tumorigenic [24]
Primary Research Model Utility	Developmental studies, toxicology	Cancer immunotherapy research [27]	Regeneration studies, therapy resistance [30] [24]

Experimental Protocols for 3D Organoid Culture

The following protocols are adapted for 3D organoid and spheroid models to investigate caspase dynamics and its functional consequences.

Protocol 1: Real-Time Monitoring of Caspase-3/7 Activity in 3D Organoids

This protocol utilizes a stable fluorescent reporter system to dynamically track apoptosis in live 3D cultures [11].

• Principle: A lentiviral-delivered biosensor (e.g., ZipGFP) contains a caspase-3/7-specific DEVD cleavage motif. Caspase activity separates GFP fragments, allowing fluorescent reconstitution, which is tracked via live-cell imaging [11].
• Materials:
  • Stable reporter cell line (e.g., ZipGFP-DEVD-mCherry) [11]
  • Matrigel or Cultrex for 3D embedding
  • 96-well optical-bottom plate (e.g., Nunclon Sphera, Cat. No. 174925)
  • Live-cell imaging system (e.g., IncuCyte, EVOS M7000) with environmental control
  • Apoptosis inducer (e.g., Carfilzomib 1-10 µM, Oxaliplatin 10-100 µM) [11]
  • Pan-caspase inhibitor (e.g., zVAD-FMK, 20-50 µM) as a control
• Procedure:
  • Generate Reporter Organoids: Culture stable reporter cells as 3D spheroids or organoids in Matrigel for 3-7 days until desired size is reached (recommended up to 500 µm thickness) [11] [5].
  • Treatment: Add apoptosis-inducing agent or vehicle control to the culture medium. Include a condition with co-treatment of inducer and zVAD-FMK.
  • Image Acquisition: Place the plate in the live-cell imager. Acquire GFP (caspase activity) and mCherry (cell mass/viability) fluorescence images every 2-4 hours for 48-120 hours. Maintain conditions at 37°C and 5% CO₂.
  • Data Analysis: Quantify mean GFP fluorescence intensity per organoid over time, normalized to the mCherry signal. Use analysis software (e.g., Celleste) to track single-cell activation events within organoids.
• Expected Outcome: A time-dependent increase in GFP fluorescence upon successful apoptosis induction, which is suppressed in the zVAD-FMK control group [11].

Protocol 2: Integrated Detection of Apoptosis-Induced Proliferation (AiP)

This protocol combines caspase-3/7 detection with a proliferation assay to identify compensatory proliferation in neighboring cells [11] [24].

• Principle: Caspase activity is monitored concurrently with the incorporation of a synthetic nucleoside (EdU) into newly synthesized DNA of proliferating cells.
• Materials:
  • Caspase-3/7 reporter organoids (from Protocol 1)
  • Click-iT Plus EdU Cell Proliferation Kit (e.g., Cat. No. C10644)
  • CellEvent Caspase-3/7 Green Detection Reagent (e.g., Cat. No. C10423)
  • NucBlue Live ReadyProbes Reagent (Hoechst 33342, Cat. No. R37605)
  • Paraformaldehyde (4%, e.g., Image-iT Fixative Solution, Cat. No. R37814)
• Procedure:
  • Pulse-Label with EdU: Treat organoids with the apoptosis-inducing agent. 24 hours post-induction, add EdU to the culture medium at a final concentration of 20 µM and incubate overnight (12-16 hours) [5].
  • Stain for Caspase-3/7 (Optional): If using a non-reporter line, add CellEvent Caspase-3/7 Green Detection Reagent (2 µM) and NucBlue (1 drop/mL) to live organoids. Incubate for 30-60 minutes at 37°C [5].
  • Fix and Permeabilize: Wash organoids with PBS and fix with 4% PFA for 1 hour at room temperature. Permeabilize using a suitable buffer (e.g., CytoVista Antibody Penetration Buffer) for 15 minutes [5].
  • Perform Click-iT Reaction: Detect the incorporated EdU using the Click-iT Plus EdU kit according to the manufacturer's instructions, which involves a copper-catalyzed covalent reaction between an EdU-azide and a fluorescent picolyl-azide dye [5].
  • Image and Analyze: Acquire z-stack images using a high-content microscope. Analyze the spatial correlation between caspase-3/7 positive (apoptotic) regions and EdU positive (proliferating) regions in the surrounding viable cell areas.
• Expected Outcome: Proliferation zones (EdU+) are expected to be adjacent to, but not overlapping with, zones of high caspase activity, indicating non-autonomous AiP [11] [24].

Protocol 3: Assessing Immunogenic Cell Death (ICD) by Surface Calreticulin Exposure

This endpoint protocol uses flow cytometry to quantify a key DAMP, surface calreticulin (ecto-CRT), a hallmark of ICD [27] [28].

• Principle: In early ICD, calreticulin translocates from the endoplasmic reticulum to the cell surface, acting as a potent "eat-me" signal for phagocytes. This is detected by an antibody without permeabilization.
• Materials:
  • 3D organoid culture
  • Known ICD inducer (e.g., Oxaliplatin, Doxorubicin) [27] [28]
  • Anti-Calreticulin antibody (for surface staining)
  • Flow cytometry buffer (PBS with 1% FBS)
  • 4% Paraformaldehyde
• Procedure:
  • Induce ICD: Treat organoids with an ICD inducer for 12-24 hours. Include a control with a non-immunogenic apoptosis inducer (e.g., UV irradiation) for comparison.
  • Prepare Single-Cell Suspension: Dissociate organoids into a single-cell suspension using gentle enzymatic digestion (e.g., TrypLE).
  • Surface Staining for CRT: Wash cells with cold flow cytometry buffer. Resuspend the cell pellet and incubate with the anti-calreticulin antibody (or isotype control) for 30 minutes on ice in the dark. DO NOT PERMEABILIZE.
  • Fixation and Analysis: Wash cells twice, resuspend in 4% PFA for fixation, and analyze by flow cytometry within 24 hours. Gate on the live cell population and compare the geometric mean fluorescence intensity (MFI) of the treated sample to the control.
• Expected Outcome: A significant increase in surface calreticulin levels in cells treated with an ICD inducer compared to controls, confirming an immunogenic phenotype [27] [28].

The following workflow diagram integrates these protocols into a coherent experimental strategy for characterizing cell death modalities in 3D organoids.

The Scientist's Toolkit: Essential Research Reagents

Successful execution of these protocols relies on a set of key reagents and tools. The following table lists essential solutions for studying caspase-mediated processes.

Table 3: Key Research Reagent Solutions for Cell Death Analysis

Reagent Category	Specific Example	Primary Function	Application Context
Caspase Reporter	ZipGFP-DEVD-mCherry Lentivirus	Real-time, specific detection of caspase-3/7 activity via fluorescence reconstitution [11]	Protocol 1 (Live imaging)
Proliferation Probe	Click-iT Plus EdU Kit	Click chemistry-based detection of DNA synthesis in proliferating cells [5]	Protocol 2 (AiP)
Viability/Cytotoxicity	LIVE/DEAD Viability/Cytotoxicity Kit	Distinguishes live vs. dead cells based on plasma membrane integrity [5]	General viability assessment
ICD Marker Antibody	Anti-Calreticulin Antibody	Detects ecto-CRT exposure on the surface of dying cells, a key DAMP [27]	Protocol 3 (ICD)
Caspase Inhibitor	zVAD-FMK (pan-caspase inhibitor)	Irreversible inhibitor of caspase activity; used as a critical control [29] [11]	All protocols (Control)
3D Culture & Imaging	CytoVista Clearing Kit	Clears and permeabilizes 3D samples for enhanced antibody and dye penetration [5]	Protocols 2 & 3 (Fixed samples)

The intricate relationship between caspase activation and downstream cellular outcomes—ranging from silent apoptosis to immunogenic cell death and reparative proliferation—is a critical frontier in cell biology, especially within complex 3D organoid models. The application notes and detailed protocols provided here equip researchers with a standardized framework to dissect these pathways. By employing real-time reporters, functional proliferation assays, and specific immunogenic markers, scientists can move beyond simply quantifying cell death to truly defining its modality and functional impact. This deeper understanding is essential for advancing applications in regenerative medicine, cancer therapy, and drug development, where modulating cell death pathways can significantly influence therapeutic outcomes.

Advanced Techniques for Real-Time Caspase Imaging and Analysis in Complex Organoid Systems

This protocol details the application of a stable, fluorescent reporter system for the real-time visualization of executioner caspase-3 and caspase-7 activity in live cells, with a specific focus on complex 3D culture models such as organoids and spheroids. Regulated cell death, particularly apoptosis, plays a central role in tissue homeostasis, disease progression, and therapeutic responses [12] [11]. Traditional endpoint assays for apoptosis, such as Annexin V binding or TUNEL staining, fail to capture the dynamic and asynchronous nature of this process, especially within 3D microenvironments that better recapitulate in vivo physiology [12] [11]. The system described herein utilizes a genetically encoded, caspase-activatable biosensor based on a split-GFP architecture, enabling high-spatiotemporal resolution tracking of apoptotic events at single-cell resolution over extended time courses [12]. Its adaptation to 3D models makes it particularly valuable for high-content screening and the mechanistic dissection of cell death modalities in physiologically relevant contexts [12] [11].

Reporter System Design and Mechanism of Action

Core Components and Molecular Architecture

The reporter system is built around a lentiviral-delivered construct featuring two primary components:

• ZipGFP Caspase-3/-7 Reporter: A biosensor where the GFP molecule is split into two parts—β-strands 1–10 and the eleventh β-strand. These fragments are tethered via a flexible linker containing a specific caspase-3/-7 cleavage motif (DEVD) [12] [11].
• Constitutive mCherry Marker: A red fluorescent protein expressed continuously, serving as a marker for successful transduction and cell presence. It provides an internal control for normalization in fluorescence-based assays [12].

Mechanism of Caspase-Dependent Fluorescence Activation

Under basal conditions, the forced proximity of the split-GFP β-strands prevents proper protein folding and chromophore maturation, resulting in minimal background fluorescence. During apoptosis, activation of executioner caspase-3 or caspase-7 induces cleavage at the DEVD motif. This cleavage separates the GFP β-strands, allowing them to spontaneously refold into the native GFP β-barrel structure. This structural reassembly leads to efficient chromophore formation and a rapid, irreversible increase in green fluorescence, providing a time-accumulating signal for caspase activation [12] [11]. The system offers substantial advantages over FRET-based reporters by minimizing background noise and enabling persistent marking of apoptotic events [12].

The following diagram illustrates the core mechanism of the ZipGFP reporter:

Key Experimental Validation and Quantitative Data

The specificity and functionality of the caspase reporter system were rigorously validated through a series of experiments. The table below summarizes key quantitative findings from these validation studies.

Table 1: Key Experimental Data from Caspase-3/-7 Reporter System Validation

Experimental Parameter	Treatment Conditions	Key Results and Quantitative Findings	Implication for System Validation
Reporter Specificity	Carfilzomib (apoptosis inducer) vs. Carfilzomib + zVAD-FMK (pan-caspase inhibitor) [12] [11]	Robust, time-dependent GFP increase with Carfilzomib; signal abrogation with zVAD-FMK co-treatment [12] [11].	Confirms caspase-dependent reporter activation.
Caspase-3/-7 Specificity	Carfilzomib treatment in caspase-3 deficient MCF-7 cells [12] [11]	Significant GFP signal induction despite caspase-3 absence [12] [11].	Demonstrates caspase-7 is sufficient for DEVD cleavage and reporter activation.
Orthogonal Apoptosis Confirmation	Western Blot and Flow Cytometry on treated reporter cells [12] [11]	Increased cleaved PARP and cleaved caspase-3 by Western; positive Annexin V/PI staining by Flow Cytometry [12] [11].	Corroborates GFP signal with established apoptotic markers.
Proliferation Tracking	Co-culture with proliferation dye [12]	Detection of proliferation in neighboring, non-apoptotic cells [12].	Enables study of apoptosis-induced proliferation (AIP).
Immunogenic Cell Death (ICD) Detection	Endpoint flow cytometry for surface calreticulin [12] [11]	Simultaneous detection of caspase activation (GFP) and ICD marker CALR [12] [11].	Facilitates study of immunogenic signaling.

Application in 3D Organoid and Spheroid Models

A significant advantage of this reporter system is its adaptability to more physiologically relevant 3D culture models, which present unique challenges for live-cell imaging, including poor reagent penetration, photobleaching, and signal heterogeneity [12] [11]. The protocol has been successfully applied to endothelial spheroids, cancer cell line-derived spheroids (e.g., MiaPaCa-2), and patient-derived organoids (PDOs), such as those from pancreatic ductal adenocarcinoma (PDAC) [11].

To facilitate high-resolution, long-term imaging of 3D structures, specialized microplate inserts can be employed. These inserts, which can be 3D-printed, are designed to hold multiple organoids in pre-defined XYZ coordinates within a standard multi-well plate [31]. This immobilization maintains the organoid within the working distance of the microscope objective and enables automated imaging acquisition over days or weeks, which is crucial for tracking developmental processes or therapy responses [31]. The constitutive mCherry signal provides a stable reference for cell presence, while normalization of the ZipGFP signal to mCherry allows for accurate interpretation of apoptosis independent of changes in cell viability or organoid size [11].

The following workflow outlines the key steps for implementing the reporter system in 3D cultures:

Detailed Experimental Protocols

Protocol 1: Generating Stable Reporter Cell Lines

Objective: To create a stable cell line expressing the ZipGFP caspase-3/-7 reporter and constitutive mCherry. Materials:

• Lentiviral vector containing ZipGFP-DEVD and mCherry constructs.
• Packaging plasmids (psPAX2, pMD2.G).
• HEK293T cells (for virus production) or target cell line of choice.
• Appropriate cell culture media and reagents.
• Polybrene.
• Puromycin or other suitable selection antibiotic.

Procedure:

• Lentivirus Production: Co-transfect HEK293T cells with the reporter lentiviral vector and packaging plasmids using a standard transfection method (e.g., PEI, calcium phosphate).
• Virus Harvest: Collect lentivirus-containing supernatant at 48 and 72 hours post-transfection. Concentrate the virus if necessary.
• Target Cell Transduction: Seed your target cells (e.g., stem cells for organoid generation, cancer cell lines). Incubate cells with the lentiviral supernatant supplemented with 4-8 µg/mL Polybrene for 24 hours.
• Selection and Expansion: 48 hours post-transduction, begin selection with the appropriate antibiotic. Maintain selection pressure for at least 5-7 days until a stable, homogeneous population is established.
• Validation: Validate reporter functionality by inducing apoptosis (e.g., with 1-10 µM Staurosporine for 4-6 hours) and confirming GFP signal induction via fluorescence microscopy or flow cytometry.

Protocol 2: Real-Time Apoptosis Imaging in 3D Organoids

Objective: To dynamically monitor caspase-3/-7 activation in 3D organoids in response to a therapeutic agent. Materials:

• Stable reporter organoids.
• Matrigel or other extracellular matrix substitute.
• 3D-printed microplate inserts (e.g., flat-cone, grid-cone designs) for 24-well glass-bottom plates [31].
• Live-cell imaging system (e.g., IncuCyte, confocal microscope with environmental chamber).
• Apoptosis-inducing agent (e.g., Carfilzomib, Oxaliplatin).
• Pan-caspase inhibitor (e.g., zVAD-FMK, 20-50 µM) for control.

Procedure:

• Organoid Seeding and Immobilization:
  • Transfer mature reporter organoids onto the tips of the 3D-printed microplate inserts pre-positioned in a 24-well plate [31].
  • Gently embed organoids in a small droplet of Matrigel and allow it to polymerize at 37°C for 20-30 minutes.
  • Carefully add pre-warmed culture medium to the well without dislodging the insert.
• Experimental Setup:
  • Pre-incubate organoids for a few hours to ensure stability.
  • Treat organoids with:
    • Vehicle control (e.g., DMSO).
    • Apoptosis inducer at desired concentration.
    • Inducer + caspase inhibitor for specificity control.
• Live-Cell Imaging:
  • Place the plate in the live-cell imaging system maintained at 37°C and 5% CO₂.
  • Program the system to acquire both GFP and mCherry (and optionally, brightfield) images from multiple positions per well at regular intervals (e.g., every 2-4 hours) for the duration of the experiment (e.g., 72-120 hours).
• Image Analysis:
  • Use image analysis software to quantify the GFP and mCherry fluorescence intensity for each organoid over time.
  • Calculate the normalized apoptosis signal as the GFP/mCherry ratio.
  • Segment images to count viable (mCherry-positive) and apoptotic (GFP-positive) cells or regions within organoids.

Protocol 3: Integrating Endpoint Immunogenic Cell Death (ICD) Analysis

Objective: To correlate real-time caspase activation with endpoint assessment of immunogenic cell death markers. Materials:

• Reporter cells or organoids post time-lapse imaging.
• Flow cytometry buffer (PBS with 1-2% FBS).
• Antibody against surface calreticulin (CALR), conjugated to a fluorophore not used in the reporter (e.g., APC).
• Flow cytometer.

Procedure:

• Sample Preparation: At the end of the live-cell imaging experiment, dissociate the reporter organoids into single-cell suspensions using enzymatic (e.g., TrypLE) and/or mechanical methods.
• Staining: Wash the cells and resuspend them in flow cytometry buffer. Stain the cells with the anti-CALR antibody according to the manufacturer's instructions. Include an isotype control.
• Flow Cytometry: Analyze the cells on a flow cytometer. Gate on viable cells and analyze the population for:
  • mCherry signal: Confirms reporter expression.
  • GFP signal: Indicates historical caspase activation during the imaging period.
  • CALR signal: Indicates immunogenic cell death.
• Data Integration: Correlate the percentage of cells that were GFP+/CALR+ with the kinetic data obtained from live imaging.

The Scientist's Toolkit: Essential Research Reagents and Materials

The table below lists key reagents and tools required for implementing the caspase biosensor system in 3D models.

Table 2: Essential Research Reagents and Materials for Caspase Reporter Studies in 3D Models

Item Name	Function/Description	Example/Catalog Consideration
DEVD-ZipGFP Caspase Reporter	Genetically encoded biosensor for caspase-3/7 activity. Core of the system.	Custom lentiviral construct as described in [12] [11].
Constitutive mCherry Marker	Fluorescent marker for cell presence and normalization control.	Co-expressed in the same lentiviral vector [12].
3D-Printed Microplate Inserts	Immobilizes organoids for long-term, high-resolution live-cell imaging.	Flat-cone, grid-cone, or suspended-grid designs for 24-well plates [31].
Live-Cell Imaging System	Automated microscope with environmental control for kinetic assays.	IncuCyte S3/LS, Celigo, or confocal microscopes with live-cell chambers.
Extracellular Matrix (ECM)	Provides a physiological 3D scaffold for organoid growth.	Cultrex Basement Membrane Extract, Matrigel [11].
Apoptosis Inducers	Positive control compounds to validate reporter function.	Carfilzomib (1-10 µM), Oxaliplatin (10-100 µM) [12] [11].
Caspase Inhibitor	Specificity control to confirm caspase-dependent signal.	zVAD-FMK (pan-caspase inhibitor, 20-50 µM) [12] [11].
Anti-Calreticulin Antibody	For endpoint detection of immunogenic cell death (ICD) by flow cytometry.	Anti-CALR-APC (or other compatible fluorophore) [12] [11].

Within the field of 3D organoid culture research, the ability to genetically engineer stable organoid lines has become a cornerstone for investigating cellular processes like apoptosis. This protocol details the application of lentiviral transduction to generate stable organoid lines, with a specific focus on downstream caspase activity monitoring for drug screening applications. Organoids, which are multicellular structures that recapitulate the architectural and functional features of original tissues, offer a unique advantage over classical 2D cell lines for such studies [32]. However, their complex 3D nature and the dynamic presence of multiple cell lineages, including stem and differentiated cells, present distinct challenges for genetic manipulation. Successful transgene expression is dependent on targeting the stem cell compartment, as only these cells ensure the long-term, stable propagation of the genetic modification throughout the organoid culture [32]. The methodology described herein leverages lentiviral transduction—a highly efficient method for stable genetic modification—to create organoid models that can be used in conjunction with optimized luminescent assays, such as the Caspase-Glo 3/7 3D Assay, to quantitatively measure drug-induced apoptosis [13] [33]. This integrated approach from setup to readout provides a robust framework for preclinical drug evaluation in a highly physiologically relevant context.

Key Reagent Solutions for Lentiviral Transduction of Organoids

The following table summarizes the essential reagents and their applications for successfully generating stable organoid lines via lentiviral transduction.

Table 1: Key Research Reagent Solutions for Lentiviral Transduction and Organoid Culture

Item	Function/Application in Protocol	Key Considerations
Lentiviral Plasmids	Delivery of genetic cargo (e.g., reporter genes, shRNA, ORF) into the host genome.	Typically a 3rd generation system is used for safety [34]. The promoter (e.g., EF1α, PGK) should be chosen to minimize epigenetic silencing in stem cells [32].
Polybrene	A cationic polymer that enhances viral infection efficiency by reducing electrostatic repulsion.	Used at 6-8 μg/mL [35]. Can be toxic to some cell types; optimal concentration should be determined.
Puromycin	A selection antibiotic for enriching successfully transduced cells.	A kill curve must be established beforehand to determine the minimal lethal concentration for the specific organoid line [34] [36].
Rho-kinase (ROCK) Inhibitor	Suppresses anoikis (cell death due to detachment) during organoid single-cell dissociation.	Critical for ensuring the survival and outgrowth of single organoid cells post-transduction [32].
Matrigel / ECM	Provides a three-dimensional extracellular matrix to support organoid growth and structure.	Mimics the native stem cell niche environment.
Caspase-Glo 3/7 3D Assay	A homogeneous, luminescent assay for quantifying caspase-3/7 activity in 3D organoid cultures.	Specifically optimized for 3D model penetration and requires no medium removal, enabling easy workflow integration [13] [33].
CellTiter-Glo 3D Cell Viability Assay	A luminescent assay for quantifying ATP levels, thereby determining the number of viable cells in 3D culture.	Can be multiplexed with cytotoxicity assays for a more complete picture of cell health [33].

Lentiviral Transduction Workflow for Organoids

The process of generating stable organoid lines requires careful planning and execution. The diagram below outlines the major experimental stages and their logical progression.

Detailed Experimental Protocol

A. Lentivirus Production

The following steps outline the production of lentiviral particles using a third-generation packaging system, which is replication-incompetent and offers a high safety profile [34].

• Day 0: Seed HEK293T Producer Cells: Seed approximately 2-3 million HEK293T cells in a 10 cm² plate in complete DMEM medium. The cells should be around 70-80% confluent for transfection the next day [34].
• Day 1: Transfection: For each 10 cm² plate, prepare the transfection mix in a sterile 1.5 mL tube:
  • Plasmids: 1.5 µg transfer plasmid (with your gene of interest), 2.0 µg packaging plasmid (e.g., pCMV-dR8.2), and 0.5 µg envelope plasmid (e.g., pCMV-VSV-G) [34].
  • Transfection Reagent: Mix the plasmids with 12 µL of X-tremeGENE 9 transfection reagent in 1 mL of Opti-MEM reduced serum medium.
  • Incubate: Incubate the mix for 20 minutes at room temperature.
  • Apply to Cells: Add the transfection mix dropwise to the HEK293T cells, which have been refreshed with 9 mL of complete DMEM. Incubate the plate at 37°C for 48 hours [34].
• Day 3: Collect Viral Supernatant: Collect the supernatant containing the lentiviral particles using a sterile pipette. Filter the supernatant through a 0.45 µm PVDF filter to remove any residual producer cells. The filtered viral supernatant can be used immediately or snap-frozen on dry ice/liquid nitrogen and stored at -80°C [34]. A second collection can be performed on Day 4 by adding fresh medium to the producer cells [34].

B. Organoid Transduction and Selection

This section details the critical steps for preparing organoids for transduction and selecting successfully modified cells.

• Organoid Dissociation: Gently dissociate the organoids into single cells using a gentle enzyme solution like Accutase. This step is crucial to expose the stem cells to the viral particles. To prevent anoikis, a Rho-kinase inhibitor (e.g., Y-27632) must be added to the medium during and after dissociation [32].
• Transduction: Seed the dissociated organoid cells in a matrix droplet or low-attachment plate. Add the filtered viral supernatant directly to the cells. Supplement the culture medium with Polybrene at a final concentration of 6-8 µg/mL to enhance infection efficiency [35]. The multiplicity of infection (MOI) should be optimized, but for hard-to-transduce cells, a higher MOI may be necessary [35].
• Selection and Outgrowth: After 24-48 hours of transduction, replace the virus-containing medium with fresh organoid culture medium containing the appropriate selection antibiotic (e.g., puromycin). The concentration of the antibiotic must be predetermined by performing a kill curve on non-transduced organoids to find the lowest concentration that kills all cells within 3-7 days [34] [36]. Continue selection until a stable, resistant population of organoids emerges. The outgrowth of transduced organoids can be favored by supplementing the medium with optimized recombinant growth factors like Wnt agonists [32].

C. Validation and Clonal Line Generation

• Validation: Validate the successful integration and expression of the transgene using methods such as fluorescence microscopy (if a reporter like GFP is used), PCR for genetic validation, and Western blot to confirm protein expression [35].
• Generating Clonal Lines: To ensure genetic homogeneity, generate clonal organoid lines. This can be achieved by manually picking individual organoids or by using advanced technologies like the CellRaft AIR System to isolate single organoids based on phenotypic properties [33]. These clonal lines can then be expanded and cryopreserved for future use.

Quantitative Parameters for Experimental Design

Successful transduction and assay performance depend on optimizing key quantitative parameters. The tables below summarize critical values for experimental setup and readout normalization.

Table 2: Key Quantitative Parameters for Lentiviral Transduction

Parameter	Typical Range/Value	Protocol Application
HEK293T Seeding Density	2-3 million cells per 10 cm² plate [34]	Ensures 70-80% confluency for efficient transfection.
Polybrene Concentration	6-8 μg/mL [35]	Enhances viral infection efficiency; must be freshly prepared.
Puromycin Selection Duration	3-7 days [35]	Continues until all cells in non-transduced control are dead.
Viral Supernatant Storage	-80°C for several months [34]	Avoid multiple freeze-thaw cycles to preserve viral titer.

Table 3: Parameters for Reproducible Caspase Activity Assays in Organoids

Parameter	Impact on Readout	Recommendation
Organoid Size	Significantly impacts well-to-well variability in assay results [33].	Size-select organoids (e.g., 300-500 µm diameter) for consistent, reproducible data and reliable EC50 determination [33].
Assay Type	Defines the specific apoptotic parameter measured.	Use the Caspase-Glo 3/7 3D Assay for quantitative, luminescent-based caspase activity measurement in a simple "add-mix-measure" protocol [13].
Multiplexing Potential	Allows for concurrent measurement of multiple cell health parameters from a single well.	The Caspase-Glo 3/7 3D Assay can be multiplexed with viability assays (e.g., CellTiter-Glo 3D) for a more comprehensive view of treatment effects [33].

Caspase Activity Monitoring as a Functional Readout

Integrating a functional assay, such as monitoring caspase activity, is essential for validating the utility of the generated stable organoid lines in drug screening. The Caspase-Glo 3/7 3D Assay is specifically designed for this purpose in 3D cultures. The assay reagent contains a luminogenic substrate that is cleaved by activated caspase-3 and -7, key effector caspases in the apoptosis pathway, to generate a luminescent signal. This signal is proportional to the amount of caspase activity present, providing a direct and quantitative readout of apoptosis induction [13].

The workflow is straightforward and amenable to high-throughput screening. After treating the stable organoid lines with compounds of interest, the homogeneous Caspase-Glo 3/7 3D reagent is added directly to the well. Following a incubation period to allow for cell lysis and caspase reaction, the luminescence is measured. This "add-mix-measure" protocol requires no intermediate washing or medium removal steps, simplifying the process and reducing potential for error [13] [33]. As demonstrated in case studies, this approach can successfully detect dose-dependent activation of caspase activity in organoids treated with apoptotic agents, such as ethanol in neuronal organoids [33]. This validates the entire pipeline from lentiviral transduction to a biologically relevant functional endpoint.

The study of caspase dynamics is fundamental to understanding programmed cell death (apoptosis) in health and disease. Caspases, a family of cysteine-dependent proteases, serve as crucial regulators and executioners of apoptosis, with caspase-3 and -7 acting as key effector enzymes that dismantle cellular components during the final stages of cell death [11] [37]. In traditional two-dimensional (2D) monolayer cultures, caspase activity has been extensively characterized using endpoint assays such as western blotting, flow cytometry, and immunofluorescence [38]. However, these methods provide limited insight into the dynamic, asynchronous nature of apoptosis as it occurs within complex tissue environments [11].

The emergence of three-dimensional (3D) cell culture models, including spheroids, tumoroids, and patient-derived organoids, has revolutionized cell death research by providing a more physiologically relevant context that recapitulates the tissue architecture, cell-cell interactions, and microenvironmental gradients found in vivo [39]. These 3D models preserve tissue-specific functions and demonstrate improved predictive value for drug screening and therapeutic response assessment, particularly in cancer research and regenerative medicine [39] [40]. Despite these advantages, the adoption of 3D models for caspase research has presented significant technical challenges, including poor reagent penetration, light scattering in thick specimens, and difficulties in maintaining long-term culture viability during imaging [11] [41].

This Application Note addresses these challenges by presenting optimized strategies for monitoring caspase dynamics with single-cell resolution in 3D models using genetically encoded fluorescent reporters and complementary detection methodologies. By integrating these approaches, researchers can achieve unprecedented spatial and temporal resolution of apoptotic events within complex 3D microenvironments, advancing our understanding of fundamental biology and accelerating drug discovery pipelines.

Technical Approaches for Caspase Detection in 3D Cultures

Genetically Encoded Fluorescent Reporters for Real-Time Caspase Imaging

Genetically encoded fluorescent reporters represent the most advanced technology for monitoring caspase dynamics in live 3D cultures with single-cell resolution. These biosensors leverage the specificity of caspase cleavage sequences coupled with engineered fluorescent proteins to provide irreversible, time-accumulating signals of caspase activation [11] [42].

The ZipGFP-based caspase-3/-7 reporter exemplifies this approach, utilizing a split-GFP architecture where the eleventh β-strand is tethered to β-strands 1-10 via a flexible linker containing the caspase-specific DEVD cleavage motif [11]. In the inactive state, forced proximity of the β-strands prevents proper folding and chromophore maturation, resulting in minimal background fluorescence. During apoptosis, caspase-3/-7-mediated cleavage at the DEVD site liberates the eleventh β-strand, enabling spontaneous refolding into the native GFP β-barrel structure with efficient chromophore formation and fluorescence recovery [11]. This system provides substantial advantages over conventional single-fluorophore or FRET-based caspase reporters by minimizing background noise, enhancing signal stability, and enabling persistent marking of apoptotic events at the single-cell level [11].

Table 1: Comparison of Caspase Detection Methods for 3D Cultures

Method Type	Detection Principle	Spatial Resolution	Temporal Resolution	Key Advantages	Key Limitations
Genetically Encoded Reporters (e.g., ZipGFP-DEVD)	Caspase-mediated cleavage and fluorescence reconstitution	Single-cell	Real-time (minutes to days)	Low background, irreversible signal, compatible with long-term imaging	Requires genetic modification
Fluorogenic Substrate Assays (e.g., CellEvent Caspase-3/7)	Caspase-mediated substrate cleavage and DNA binding	Single-cell	Near real-time (30 min to hours)	No-wash protocol, applicable to various 3D models	Reagent penetration issues in dense spheroids
Immunofluorescence Staining	Antibody binding to active caspases	Single-cell	End-point only	High specificity, multiplexing capability	Requires fixation, no live dynamics
Luminescent Assays (e.g., Caspase-Glo 3/7 3D)	Caspase-mediated substrate cleavage and luminescence	Population average	End-point only	High sensitivity, quantitative, optimized for 3D	No spatial information, requires lysis

For implementation in 3D cultures, researchers have successfully generated stable cell lines expressing the ZipGFP-DEVD reporter alongside a constitutive mCherry marker for normalization [11]. This dual-reporter system has been validated in both engineered spheroids and patient-derived organoid models, demonstrating time-dependent increases in GFP fluorescence following apoptosis induction with agents such as the proteasome inhibitor carfilzomib [11]. The specificity of this reporter system was confirmed through caspase inhibition experiments using zVAD-FMK, which effectively abrogated the GFP signal [11].

Complementary Caspase Detection Methodologies

While genetically encoded reporters provide unparalleled dynamic information, several complementary methods offer alternative approaches for caspase detection in 3D cultures. Fluorogenic substrate assays, such as CellEvent Caspase-3/7 Green detection reagent, utilize cell-permeant substrates comprising the DEVD peptide conjugated to a nucleic acid-binding dye [43]. In apoptotic cells with activated caspase-3/7, the dye is cleaved from the DEVD peptide and becomes free to bind DNA, producing a bright fluorescent signal [43]. These assays require no wash steps, preserving fragile apoptotic cells that might be lost during processing, and the signal survives formaldehyde fixation, enabling endpoint analysis and immunocytochemical probing [43].

For higher-throughput screening applications without spatial resolution requirements, luminescent assays like the Caspase-Glo 3/7 3D Assay provide a robust solution [41]. This bioluminescent method has been specifically optimized for 3D structures, including spheroids and extracellular matrix-embedded tissues, enabling sensitive quantification of caspase activity without the need for cell lysis or dissociation [41]. Validation studies have demonstrated that this assay can detect size-dependent apoptotic responses in spheroids, with larger HepG2 spheroids showing increased susceptibility to chemotherapeutic agents like Panobinostat [41].

Immunofluorescence staining remains a valuable approach for fixed samples, allowing precise subcellular localization of active caspases using specific antibodies [38]. This method is particularly advantageous when co-localization with other markers or detailed morphological assessment is required, though it precludes live-cell analysis [38].

Experimental Protocols for 3D Caspase Imaging

Protocol 1: Implementing the ZipGFP Caspase Reporter in 3D Organoids

This protocol outlines the procedure for monitoring caspase-3/7 dynamics in patient-derived organoids using the stable ZipGFP-DEVD reporter system, enabling real-time visualization of apoptosis with single-cell resolution.

Materials Required:

• Lentiviral ZipGFP-DEVD caspase-3/7 reporter construct with constitutive mCherry marker
• Target cells for organoid formation
• Appropriate organoid culture medium and extracellular matrix (e.g., Cultrex, Matrigel)
• Apoptosis-inducing agents (e.g., carfilzomib, oxaliplatin) and controls
• Pan-caspase inhibitor (zVAD-FMK) for specificity controls
• Live-cell imaging chamber with controlled environment (37°C, 5% CO₂)
• Confocal or spinning disk microscope system with environmental control
• Image analysis software (e.g., ImageJ, Imaris, or manufacturer-specific AI modules)

Methodology:

• Stable Cell Line Generation:
  • Transduce target cells with lentiviral ZipGFP-DEVD reporter using standard protocols
  • Select stable clones using appropriate antibiotics and confirm reporter expression via fluorescence microscopy
  • Validate reporter functionality using established apoptotic inducers (e.g., 1-10 μM staurosporine for 4-6 hours) and caspase inhibitors (10-30 μM zVAD-FMK)

• 3D Organoid Establishment:

  • Embed reporter-expressing cells in extracellular matrix (e.g., 70% Cultrex) following established organoid culture protocols
  • Overlay with appropriate organoid culture medium and maintain at 37°C, 5% CO₂
  • Culture for 5-14 days to allow organoid formation, refreshing medium every 2-3 days

• Live-Cell Imaging and Apoptosis Induction:

  • Pre-equilibrate organoids in imaging chamber with controlled environment (37°C, 5% CO₂)
  • Establish baseline fluorescence imaging (GFP: Ex/Em 488/530 nm; mCherry: Ex/Em 587/610 nm)
  • Treat organoids with apoptotic stimuli and include control groups (vehicle alone and caspase inhibitor co-treatment)
  • Acquire time-lapse images at 15-30 minute intervals over 24-120 hours using confocal or spinning disk microscopy

• Image Analysis and Quantification:

  • Process images using background subtraction and flat-field correction algorithms
  • Segment individual cells using the constitutive mCherry signal
  • Quantify GFP fluorescence intensity in segmented regions over time
  • Normalize GFP signals to mCherry fluorescence to account for potential viability changes
  • Apply statistical analyses to determine significance of treatment effects

Table 2: Quantitative Validation Data for ZipGFP Caspase-3/7 Reporter System [11]

Validation Parameter	Experimental Condition	Result	Significance
Reporter Specificity	Carfilzomib + zVAD-FMK	>90% signal inhibition	Confirms caspase-dependent activation
Dynamic Range	Carfilzomib vs. DMSO control	>10-fold increase in GFP signal	Enables sensitive apoptosis detection
Temporal Response	Time-course post-induction	Signal detectable within 2-4 hours	Captures early apoptotic events
Application in 3D Models	PDAC organoids & HUVEC spheroids	Robust GFP induction in 3D context	Validates utility in physiologically relevant models
Caspase-3 Independence	MCF-7 cells (caspase-3 deficient)	Significant GFP signal maintained	Confirms caspase-7-mediated activation

Protocol 2: Multiplexed Caspase and Immunogenic Cell Death Detection

This advanced protocol enables simultaneous monitoring of caspase activation and immunogenic cell death (ICD) markers in 3D models, providing insights into the immunogenic potential of apoptotic cells.

Materials Required:

• ZipGFP-DEVD reporter cells as in Protocol 1
• Anti-calreticulin antibody for surface exposure detection
• Fluorophore-conjugated secondary antibodies compatible with GFP/mCherry
• Flow cytometry buffer (PBS with 1-5% FBS)
• Proliferation tracking dye (e.g., CellTrace) for apoptosis-induced proliferation studies
• Fixation and permeabilization reagents if intracellular staining required

Methodology:

• 3D Culture and Treatment:
  • Establish 3D spheroids or organoids as described in Protocol 1
  • Treat with immunogenic cell death inducers (e.g., oxaliplatin, anthracyclines) or appropriate controls

• Live-Cell Imaging Phase:

  • Perform time-lapse imaging of caspase activation using the ZipGFP reporter as in Protocol 1
  • For apoptosis-induced proliferation studies, pre-label a subset of cells with proliferation dye according to manufacturer's instructions prior to 3D culture establishment

• Endpoint ICD Analysis:

  • Harvest 3D structures at desired timepoints and dissociate using gentle enzymatic treatment (e.g., Accutase or collagenase I, optimized for specific model)
  • Stain single-cell suspensions with anti-calreticulin antibody in flow cytometry buffer for 30-60 minutes on ice
  • Wash and incubate with fluorophore-conjugated secondary antibody if required
  • Analyze by flow cytometry, gating on GFP-positive (apoptotic) and GFP-negative populations
  • Quantify calreticulin surface exposure in apoptotic versus non-apoptotic populations

• Data Integration:

  • Correlate temporal caspase activation patterns from live imaging with endpoint ICD markers
  • Assess spatial relationships between caspase activation and proliferation zones in 3D structures

Successful implementation of caspase dynamics monitoring in 3D cultures requires careful selection of reagents and tools. The following table summarizes key solutions validated for 3D apoptosis research.

Table 3: Essential Research Reagent Solutions for 3D Caspase Imaging

Reagent/Category	Specific Examples	Function/Application	Key Considerations for 3D Cultures
Genetically Encoded Caspase Reporters	ZipGFP-DEVD caspase-3/7 sensor	Real-time apoptosis tracking in live cells	Optimal with constitutive fluorescent marker (e.g., mCherry) for normalization
Fluorogenic Caspase Substrates	CellEvent Caspase-3/7 Green	No-wash detection of caspase-3/7 activity	Verify penetration into core of dense spheroids; may require extended incubation
3D Culture Matrices	Cultrex, Matrigel	Provide physiological scaffolding for 3D growth	Batch variability may affect organoid formation; maintain temperature during handling
Apoptosis Inducers	Carfilzomib, Oxaliplatin, Staurosporine	Positive controls for caspase activation	Titrate concentration for specific 3D models; core penetration may be limited
Caspase Inhibitors	zVAD-FMK (pan-caspase)	Specificity controls for caspase-dependent signals	Use in co-treatment experiments to confirm signal specificity
3D-Optimized Luminescent Assays	Caspase-Glo 3/7 3D	Sensitive caspase activity quantification in intact 3D models	Validated for spheroids and matrix-embedded cultures; no spatial information
Dissociation Reagents	TrypLE, Accutase, Collagenase I	3D structure dissociation for endpoint analysis	Optimization required: TrypLE may damage surface markers; collagenase preserves antigens

The integration of advanced live-cell imaging technologies with physiologically relevant 3D culture models represents a transformative approach for studying caspase dynamics with single-cell resolution. The strategies outlined in this Application Note provide researchers with robust methodologies for monitoring apoptotic events within complex tissue-like environments, enabling unprecedented insight into the spatial and temporal regulation of cell death. The ZipGFP-based reporter system and complementary detection methods offer versatile solutions for diverse research applications, from fundamental investigations of caspase biology to preclinical drug screening.

Future developments in this field will likely focus on expanding the multiplexing capabilities to simultaneously monitor multiple caspase family members and integrating biosensors for complementary pathways such as pyroptosis and necroptosis [11]. Additionally, continued refinement of imaging modalities and analysis algorithms will enhance our ability to resolve single-cell dynamics within increasingly complex and larger 3D structures. As these technologies mature, they will undoubtedly advance our understanding of cell death mechanisms in physiological and pathological contexts, accelerating the development of novel therapeutic strategies for cancer, neurodegenerative disorders, and other diseases characterized by dysregulated apoptosis.

The study of regulated cell death, particularly within complex 3D organoid cultures, is crucial for advancing our understanding of tissue homeostasis, disease progression, and therapeutic responses in physiologically relevant systems [12]. A significant challenge in this field has been the dynamic capture of apoptotic kinetics alongside key immunogenic markers in a single, cohesive assay. This application note details a robust methodology for multiplexed endpoint analysis, enabling researchers to correlate the activation of executioner caspases-3/7 with the surface exposure of calreticulin (CALR), a definitive hallmark of immunogenic cell death (ICD) [12] [44]. By integrating a live-cell caspase activity biosensor with endpoint flow cytometric detection of CALR, this protocol provides a high-content framework for the mechanistic dissection of cell death pathways in 3D models, directly supporting drug discovery and development efforts.

Key Research Reagent Solutions

The following table catalogues the essential reagents and tools required to implement the described multiplexed analysis.

Table 1: Essential Research Reagents and Materials

Reagent/Material	Function/Application	Key Details
ZipGFP Caspase-3/7 Reporter	Genetically encoded biosensor for real-time apoptosis imaging	Split-GFP system with DEVD cleavage motif; low background, irreversible fluorescence upon caspase activation [12].
Constitutive mCherry Marker	Fluorescent marker for cell presence and normalization	Serves as a transfection control and internal standard for fluorescence assays [12].
Anti-Calreticulin Antibody	Detection of surface CALR exposure by flow cytometry	Must be compatible for live-cell staining to detect surface-exposed CALR, an "eat me" signal for ICD [12] [44].
Carfilzomib	Apoptosis inducer (Proteasome inhibitor)	Used for positive control induction of caspase-3/7 activity and subsequent ICD [12].
zVAD-FMK (pan-caspase inhibitor)	Caspase activity inhibitor	Used as a negative control to confirm caspase-dependence of the ZipGFP signal [12].
ATR Inhibitors (e.g., VE822, AZD6738)	Radiosensitizers and immunogenic death inducers	Can be combined with radiation to enhance ICD hallmarks, including HMGB1 release and ATP secretion [44].
Human Organoid Growth Medium (e.g., IntestiCult OGM-h)	Cultivation and maintenance of 3D organoids	Supports the growth and differentiation of patient-derived or stem cell-derived organoids [45].
Growth Factor-Reduced Matrigel	Extracellular matrix for 3D organoid culture	Provides a scaffold for organoid formation and growth [45].

Experimental Workflow and Signaling Pathways

The integrated protocol for caspase activity monitoring and endpoint immunogenic marker analysis follows a sequential workflow, culminating in a multiplexed data output. The diagram below outlines the key experimental stages.

Figure 1: Experimental workflow for multiplexed caspase and calreticulin analysis.

The core signaling pathways investigated in this assay converge on the induction of immunogenic cell death. The following diagram illustrates the key molecular events and their connections.

Figure 2: Signaling pathways linking caspase activation to immunogenic cell death.

Detailed Experimental Protocol

Generation of Stable Caspase Reporter Cells for 3D Culture

• Objective: Create stable 2D cell lines or 3D organoids expressing the ZipGFP-based caspase-3/7 reporter and a constitutive mCherry fluorescent marker [12].
• Procedure:
  • Lentiviral Transduction: Utilize a lentiviral delivery system to stably integrate the caspase reporter construct into your target cells. The construct should contain the ZipGFP-DEVD biosensor and a constitutively expressed mCherry protein.
  • Selection and Expansion: Apply appropriate selection antibiotics (e.g., puromycin) for 1-2 weeks to select for successfully transduced cells. Expand the stable polyclonal population.
  • 3D Organoid Culture:
    • For organoid generation, mix the reporter cells with growth factor-reduced, phenol red-free Matrigel matrix [45].
    • Plate the cell-Matrigel mixture as domes in a pre-warmed culture plate and incubate at 37°C for 30 minutes to allow for solidification.
    • Overlay with appropriate organoid growth medium (e.g., IntestiCult Organoid Growth Medium) supplemented with necessary factors [45].
    • Maintain cultures by passaging every 7-10 days, breaking up the Matrigel domes and dissociating organoids into smaller clusters before reseeding.

Multiplexed Assay: Live-Cell Imaging and Endpoint Flow Cytometry

• Objective: Treat reporter organoids, dynamically monitor caspase activation, and perform endpoint analysis of calreticulin surface exposure.
• Materials:
  • Stable caspase reporter organoids
  • Apoptosis inducers (e.g., 250 nM Carfilzomib [12]) and/or ICD inducers (e.g., Radiation + 250 nM ATR inhibitor VE822 [44])
  • Control compounds (e.g., DMSO, 20-50 µM zVAD-FMK [12])
  • Flow cytometry staining buffer (DPBS with 1-2% FBS)
  • Antibody for surface calreticulin detection
• Procedure:
  • Treatment: Apply the therapeutic compounds of interest to the mature reporter organoids. Include vehicle (DMSO) and caspase inhibitor (zVAD-FMK) controls.
  • Real-Time Caspase-3/7 Imaging:
    • Place the culture plate in a live-cell imaging system (e.g., IncuCyte).
    • Acquire GFP (caspase activation) and mCherry (cell presence) fluorescence images at regular intervals (e.g., every 2-4 hours) over 72-120 hours [12].
    • Use integrated software to quantify the GFP signal intensity and the number of GFP-positive objects over time, normalized to the mCherry signal.
  • Endpoint Flow Cytometry for Surface Calreticulin:
    • At a desired endpoint (e.g., 24-72 hours post-treatment), harvest organoids for flow cytometry.
    • Carefully dissociate the Matrigel domes and organoid structures into single-cell suspensions using enzyme-free dissociation buffers or gentle protease treatment (e.g., TrypLE) [45].
    • Wash cells twice with flow cytometry staining buffer.
    • Resuspend the cell pellet in staining buffer containing a fluorophore-conjugated anti-calreticulin antibody. Perform staining on ice for 20-30 minutes, protected from light.
    • Include an isotype control antibody for gating and a barcoded, unstimulated control sample for signal normalization to enhance accuracy [44].
    • Wash cells twice to remove unbound antibody and resuspend in staining buffer for analysis.
    • Analyze samples using a flow cytometer, detecting the fluorescence for the CALR antibody, GFP, and mCherry.

Data Presentation and Analysis

Quantitative Analysis of Caspase-3/7 Activation Kinetics

Data from live-cell imaging should be processed to generate kinetic plots of caspase activation. The table below summarizes typical quantitative data obtained from such experiments.

Table 2: Quantitative Caspase-3/7 Activation upon Treatment (Representative Data)

Treatment Condition	Time to Significant GFP Increase (h)	Max GFP Signal (Fold over Control)	Inhibition by zVAD-FMK
DMSO (Vehicle Control)	N/A	1.0	No
Carfilzomib (250 nM)	~24-36	8.5 - 12.0	Yes [12]
Oxaliplatin	~30-48	6.0 - 9.5	Yes [12]
Radiation + ATRi (VE822)	Variable	Variable	Partial (Dual Role of Caspases) [44]

Integrated Flow Cytometry Results for Co-Localization Analysis

Flow cytometry data allows for the direct correlation of caspase activation with immunogenic markers at a single-cell level. The following table provides an example of expected outcomes.

Table 3: Expected Flow Cytometry Endpoint Readouts for ICD Analysis

Cell Population	Caspase-3/7 (GFP+)	Surface Calreticulin+	Interpretation
Viable Cells	Negative	Negative	Healthy, untreated cells.
Early ICD Induction	Negative	Positive	Pre-apoptotic immunogenic signaling [12] [44].
Active Apoptosis	Positive	Negative / Positive	Caspase-active cell; CALR status determines immunogenic potential.
Late Apoptosis/Necrosis	Positive (may fade)	Variable	Loss of membrane integrity; secondary necrosis.

Discussion

This multiplexed endpoint analysis protocol successfully bridges dynamic live-cell imaging with high-resolution, single-cell flow cytometry. The integration of the ZipGFP caspase reporter provides a sensitive and irreversible mark of apoptosis, while the subsequent detection of surface calreticulin identifies those apoptotic events with high immunogenic potential [12]. This is particularly powerful in the context of 3D organoid models, which more accurately recapitulate the tumor microenvironment and cellular heterogeneity than traditional 2D cultures [45] [46].

A key consideration in data interpretation is the understanding that caspase activity has a dual role in immunogenicity. While it is essential for apoptosis and can promote some ICD features like ATP secretion, it can simultaneously suppress other DAMPs, such as HMGB1 release and type I interferon signaling [44]. Therefore, the combination of caspase activity with multiple ICD markers, as outlined here, provides a more complete picture of the immunogenic nature of cell death induced by novel therapeutics.

This approach is highly adaptable. The workflow can be expanded to include other ICD markers like extracellular ATP or HMGB1 [44], and is compatible with automated, high-throughput screening platforms for drug discovery in complex 3D organoid systems [46] [47].

Solving Common Challenges: A Practical Guide to Optimizing Caspase Assays in Organoid Workflows

In the field of 3D organoid culture, extracellular matrix (ECM) hydrogels such as Matrigel serve as the foundational scaffold that mimics the in vivo microenvironment, supporting complex biological processes including organoid development, maturation, and function. However, traditional animal-derived matrices like Matrigel exhibit significant batch-to-batch variability in their composition, mechanical properties, and bioactivity, which directly impacts experimental reproducibility and reliability [48] [49]. This variability presents a substantial challenge for research applications, particularly in quantitative studies such as caspase activity monitoring in response to therapeutic compounds, where precise and consistent matrix conditions are essential for obtaining biologically relevant and statistically significant data.

The inherent limitations of conventional ECM substrates have driven innovation in two parallel directions: (1) implementation of rigorous batch control and correction methodologies for existing materials, and (2) development of novel, defined synthetic hydrogel alternatives. This Application Note provides detailed protocols and analytical frameworks to address both approaches, enabling researchers to enhance reproducibility in their organoid-based research, with specific consideration for caspase activity monitoring within broader thesis research on 3D organoid cultures.

Traditional ECM hydrogels, particularly those derived from biological sources like the Engelbreth-Holm-Swarm (EHS) mouse sarcoma (e.g., Matrigel), contain a complex and undefined mixture of ECM proteins, growth factors, and other biological molecules [49]. This complexity introduces multiple sources of variability:

• Biochemical Composition: Fluctuations in the concentrations of key components such as laminin, collagen IV, entactin, and various growth factors between production lots [49].
• Physical Properties: Variations in mechanical properties (stiffness, viscoelasticity) and structural characteristics (pore size, architecture) that significantly influence cell behavior and signaling [50] [51].
• Functional Performance: Differences in gelation kinetics, degradation rates, and bioactivity that directly affect organoid formation efficiency, growth patterns, and morphological development [48] [3].

Impact on Caspase Activity Monitoring and Drug Screening

In the specific context of caspase activity monitoring for drug development research, matrix variability introduces confounding factors that can compromise data interpretation:

• Altered Baseline Apoptosis: Variable matrix composition can differentially influence baseline survival signaling in organoids, affecting control-level caspase readings.
• Modified Drug Penetration and Efficacy: Structural differences in hydrogel architecture can alter the diffusion kinetics of therapeutic compounds, leading to inconsistent drug exposure across experiments.
• Variable Mechanotransduction Signaling: Fluctuations in matrix stiffness can modulate mechanosensitive pathways (e.g., YAP/TAZ), which crosstalk with apoptotic signaling networks [51].

Table 1: Key Characterization Parameters for ECM Hydrogel Batch Quality Control

Parameter Category	Specific Metrics	Impact on Organoid Culture
Biochemical Composition	Protein concentration, growth factor levels (e.g., TGF-β, FGF), laminin/collagen ratio	Influences stem cell differentiation, organoid patterning, and baseline metabolic activity
Mechanical Properties	Elastic modulus (stiffness), loss/storage modulus (viscoelasticity), compression resistance	Affects cell fate decisions, organoid morphology, and mechanotransduction pathways
Structural Characteristics	Pore size, fiber architecture, degradation kinetics	Modulates nutrient diffusion, organoid size distribution, and drug penetration in screening assays
Functional Performance	Gelation time, contraction rate, cell attachment efficiency	Determines organoid formation efficiency, viability, and experimental success rate

Strategic Approaches to Batch Control and Variability Mitigation

Comprehensive Batch Quality Control Framework

Implementing a rigorous quality control protocol for incoming hydrogel batches is essential for ensuring experimental consistency. The following workflow provides a systematic approach to batch qualification:

Figure 1: Systematic workflow for qualifying incoming hydrogel batches, incorporating multi-parameter assessment to ensure consistency.

Protocol 1: Hydrogel Batch Qualification for Organoid Culture

Objective: To establish a standardized protocol for evaluating and qualifying new lots of ECM hydrogels prior to use in experimental studies, particularly those involving quantitative caspase activity measurements.

Materials:

• Test hydrogel batch (e.g., Matrigel, Cultrex BME, other ECM hydrogels)
• Reference hydrogel batch (pre-qualified lot with known performance)
• Appropriate cell line for organoid formation (e.g., intestinal stem cells, patient-derived organoids)
• Complete organoid culture medium
• 4-well chamber slides or 24-well plates
• Rheometer (e.g., rotational rheometer with temperature control)
• Protein quantification assay (e.g., BCA assay)
• SDS-PAGE equipment
• Imaging system for brightfield and fluorescence microscopy

Procedure:

• Documentation Review

  • Obtain Certificate of Analysis from manufacturer for both test and reference batches
  • Record key parameters: protein concentration, growth factor levels (if available), endotoxin testing results

• Physical Characterization

  • Prepare hydrogel samples according to manufacturer's recommendations (typically 4-8 mg/mL final concentration)
  • Using a rheometer with temperature-controlled plate:
    • Load 200μL of hydrogel solution onto measurement plate at 4°C
    • Program temperature ramp from 4°C to 37°C over 10 minutes
    • Measure storage modulus (G') and loss modulus (G") during gelation
    • Record final stiffness values at 37°C after gelation completion
  • Compare stiffness profile of test batch against reference batch
  • Acceptance criterion: ≤15% deviation in final storage modulus from reference

• Biochemical Analysis

  • Perform protein quantification using BCA assay in triplicate
  • Conduct SDS-PAGE under reducing conditions:
    • Load equal protein amounts (10μg) for test and reference batches
    • Visualize protein banding pattern with Coomassie Blue staining
    • Compare major band intensities and patterns
  • Acceptance criterion: Comparable protein concentration and banding pattern to reference

• Functional Validation

  • Prepare organoid cultures in parallel using test and reference hydrogels:
    • Plate identical cell numbers (500-1000 cells/well) in 20μL hydrogel domes in 4-well chamber slides
    • Culture for 5-7 days with appropriate medium changes
  • Assess organoid formation efficiency at day 3 and day 7:
    • Count total organoids per field of view (minimum 5 fields per replicate)
    • Categorize organoids by morphology (spherical, budded, cystic)
  • Evaluate viability and caspase activity baseline:
    • Perform live/dead staining (calcein-AM/propidium iodide)
    • Measure baseline caspase activity using fluorescent caspase substrate (e.g., DEVD-AMC)
  • Acceptance criterion: ≥80% of reference batch performance in formation efficiency and comparable viability/caspase baseline

Quality Control Documentation:

• Maintain detailed records of all qualification data
• Establish internal specifications for acceptable performance
• Assign qualified batch numbers for use in specific applications
• Periodically re-qualify reference standard performance

Computational Batch-Effect Correction for Proteomic Data

For researchers conducting proteomic analysis of organoid responses, batch effects in measurement data can be corrected computationally. Recent evidence demonstrates that protein-level correction represents the most robust strategy for managing batch effects in mass spectrometry-based proteomics [52].

Table 2: Comparison of Batch-Effect Correction Strategies for Proteomic Data

Correction Level	Recommended Algorithms	Advantages	Limitations
Precursor-Level	NormAE, WaveICA2.0	Early correction minimizes propagation of technical variance	Requires specialized input parameters (m/z, retention time)
Peptide-Level	Combat, RUV-III-C, Median Centering	Moderate performance across different experimental designs	Inconsistent performance when batch and biology are confounded
Protein-Level	Ratio, MaxLFQ, Harmony, Combat	Most robust performance, especially in confounded designs	May retain some technical variance from earlier processing steps

Protocol 2: Protein-Level Batch-Effect Correction for Organoid Proteomic Data

Objective: To implement optimal batch-effect correction strategies for proteomic data derived from organoids cultured across different hydrogel batches or experimental runs.

Materials:

• Raw or processed proteomic intensity data
• R or Python statistical programming environment
• Appropriate batch-effect correction packages (e.g., sva, limma, Harmony)

Procedure:

• Data Preparation

  • Compile protein intensity data from multiple batches/experimental runs
  • Annotate samples with batch identifiers and experimental conditions
  • Log2-transform intensity values to approximate normal distribution

• Batch Effect Assessment

  • Perform Principal Component Analysis (PCA) to visualize batch clustering
  • Use PVCA (Principal Variance Component Analysis) to quantify variance attributable to batch effects
  • Proceed with correction if batch explains >10% of total variance

• Batch-Effect Correction Using Ratio Method with MaxLFQ

  • For studies with universal reference samples:
    • Calculate ratio of study sample intensities to reference sample intensities for each protein
    • Use these ratios for downstream analysis
  • For studies without reference samples:
    • Implement MaxLFQ algorithm for protein quantification
    • Apply ComBat or Harmony adjustment to protein-level data
    • Validate correction efficiency using PCA visualization

• Validation of Correction

  • Confirm reduction of batch clustering in PCA plots
  • Verify preservation of biological signals through positive controls
  • Assess quantitative recovery of known differential expressions

Advanced Solutions: Defined and Synthetic Hydrogel Platforms

Engineered Hydrogel Systems for Enhanced Reproducibility

To overcome the inherent limitations of animal-derived matrices, several engineered hydrogel platforms have been developed with precisely controlled compositions and properties:

Hybrid Hydrogel-ECM Scaffolds: The DECIPHER (DEcellularized In situ Polyacrylamide Hydrogel–ECM hybRid) platform enables independent tuning of mechanical properties while maintaining native ECM composition and architecture [50]. This system allows researchers to decouple biochemical and mechanical cues, revealing that young ECM ligand presentation can counteract profibrotic stiffness cues in aged microenvironments [50].

Fully Synthetic Animal-Free Systems: PIC (polyisocyanopeptide)-invasin hydrogels represent a completely defined, animal-free alternative that supports long-term 3D organoid culture [53]. These thermoreversible hydrogels offer excellent optical clarity for imaging and eliminate lot-to-lot variability associated with traditional matrices.

Computationally Designed Hydrogels: Machine learning approaches now enable predictive design of ECM-mimetic hydrogels with tailored rheological properties [54]. These AI-guided platforms significantly reduce development time and optimize hydrogel formulations for specific organoid applications.

Protocol for Transitioning to Defined Hydrogel Systems

Protocol 3: Adapting Organoid Cultures to Defined Synthetic Hydrogels

Objective: To successfully transition organoid cultures from traditional Matrigel to defined synthetic hydrogel systems with minimal disruption to experimental workflow.

Materials:

• PIC-invasin hydrogel or other defined synthetic hydrogel system
• Traditional ECM hydrogel (Matrigel) for control comparisons
• Organoid culture cells
• Complete culture medium
• 4-well chamber slides

Procedure:

• Parallel Culture Establishment

  • Prepare both traditional ECM hydrogels and synthetic hydrogels according to manufacturer specifications
  • Plate identical cell numbers in both matrix systems in parallel wells
  • Maintain cultures with identical medium formulations and feeding schedules

• Progressive Adaptation

  • For sensitive cell types, employ a gradual transition strategy:
    • Initial passage: 75% traditional ECM / 25% synthetic hydrogel
    • Second passage: 50% traditional ECM / 50% synthetic hydrogel
    • Third passage: 25% traditional ECM / 75% synthetic hydrogel
    • Fourth passage: 100% synthetic hydrogel
  • Monitor organoid formation efficiency and morphology at each passage

• Functional Validation

  • Compare key functional metrics between systems:
    • Organoid formation efficiency
    • Growth rates and size distribution
    • Cell type composition (via immunostaining)
    • Baseline caspase activity and drug response profiles
  • Optimize matrix concentration based on functional outcomes

• Protocol Optimization

  • Adjust hydrogel stiffness by varying polymer concentration
  • Modify adhesive ligand density if needed for specific cell types
  • Optimize degradation kinetics through crosslinking density

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Research Reagent Solutions for Reproducible Hydrogel-Based Organoid Culture

Reagent Category	Specific Products	Function & Application	Reproducibility Considerations
Traditional ECM Hydrogels	Corning Matrigel, Cultrex BME, Collagen I	Provide complex biological cues for demanding organoid cultures	High lot-to-lot variability; requires rigorous batch QC
Synthetic Hydrogel Platforms	PIC-Invasin Gel, PEG-Based Systems, HyStem-HP	Chemically defined matrices with precise mechanical control	Excellent batch consistency; may require culture adaptation
Hybrid ECM-Hydrogel Systems	DECIPHER Platform, dECM-Based Hydrogels	Combine native ECM biology with tunable mechanical properties	Moderate consistency; dependent on ECM source
Quality Control Tools	Rheometers, BCA Protein Assay, SDS-PAGE Systems	Characterize mechanical and biochemical hydrogel properties	Essential for establishing batch acceptance criteria
Batch Correction Software	R (sva, limma packages), Python (Scanpy, Harmony), Progenesis QI	Computational correction of technical variability in omics data	Critical for multi-batch experimental designs

Ensuring reproducibility in organoid research requires a systematic approach to hydrogel batch control that integrates both practical laboratory protocols and computational correction strategies. By implementing the quality control frameworks, validation protocols, and advanced hydrogel systems outlined in this Application Note, researchers can significantly enhance the reliability of their organoid models, particularly for sensitive applications like caspase activity monitoring in drug screening. The field is moving increasingly toward defined, synthetic matrix platforms that offer superior reproducibility while maintaining biological relevance, representing the future standard for robust organoid research.

Figure 2: Integrated framework for achieving reproducibility, combining quality control of traditional materials with adoption of defined synthetic hydrogels.

Optimizing Seeding Density and Culture Conditions to Prevent Necrosis and Ensure Healthy Organoids

Within the burgeoning field of 3D organoid culture, maintaining cellular viability and preventing uncontrolled cell death, such as necrosis, is paramount for generating physiologically relevant models. Necrosis not only disrupts the intricate architecture of organoids but also triggers inflammatory pathways that can compromise experimental outcomes in drug screening and disease modeling. This application note provides a detailed framework for optimizing seeding density and culture conditions, with a specific focus on integrating real-time caspase activity monitoring as a critical quality control metric. By embedding this dynamic readout into routine culture assessment, researchers can proactively ensure organoid health and integrity, thereby enhancing the reliability of data generated for research and drug development.

Quantitative Data for Culture Optimization

Summarized below are key parameters for establishing robust organoid cultures across different tissue types, providing a baseline for preventing stress-induced necrosis.

Table 1: Optimized Seeding Densities for Various Organoid Types

Organoid Type	Recommended Seeding Density (cells/μL Matrigel)	Recommended Well Format	Key Supporting Evidence
Mouse Intestinal	200 - 500 cells/μL [55]	96-well plate [55]	Single cells form budding organoids; low density prevents hypoxia.
Patient-Derived Pancreatic (PDAC)	Information not specified in search results	Information not specified in search results	Heterogeneous structures require density optimization for viability.
Human Cerebral	Information not specified in search results	U-bottom 96-well plates [56]	Controlled aggregation ensures consistent structure and reduces core necrosis.
Mouse Liver (mLOs)	Information not specified in search results	Information not specified in search results	Platform mimics in vivo metabolism, implying need for optimized density.

Table 2: Culture Conditions and Monitoring to Prevent Necrosis

Parameter	Optimal Condition	Rationale & Monitoring Technique
Medium Change	Careful, scheduled changes	Avoids sudden volume shifts that damage structure; changes can cause measurable organoid volume fluctuations [55].
Viability Assessment	Real-time caspase-3/7 reporter (e.g., ZipGFP-DEVD) [11]	Provides live, single-cell resolution data on apoptosis, an early indicator of culture stress preceding necrosis.
Long-term Imaging	Light-sheet microscopy with sample stabilization [55]	Enables tracking of growth and death kinetics in 3D over days without phototoxicity.
3D Structure Validation	Patterned FEP foil wells or U-bottom plates [55] [56]	Improves sample positioning and reproducibility, preventing aggregation-induced necrosis.

Experimental Protocols

Protocol: Real-Time Caspase Activity Monitoring in Organoids

This protocol enables the dynamic tracking of apoptosis, a key indicator of suboptimal culture conditions, in 3D organoid models [11].

Key Reagents:

• Stable organoid line expressing a caspase-3/7 reporter (e.g., lentiviral-delivered ZipGFP-DEVD with constitutive mCherry marker).
• Appropriate organoid culture medium.
• Apoptosis inducer (e.g., carfilzomib) and pan-caspase inhibitor (e.g., zVAD-FMK) for validation.
• Matrigel or other ECM hydrogel.
• Live-cell imaging-compatible plate.

Methodology:

• Reporter Line Generation: Generate a stable organoid line via lentiviral transduction to express a caspase-3/7 biosensor. The biosensor should be based on a split-GFP system where the eleventh β-strand is tethered via a linker containing a DEVD cleavage motif. A constitutive fluorescent marker like mCherry should be co-expressed to normalize for cell presence and transduction success [11].
• Organoid Establishment: Seed the reporter organoids in Matrigel drops in a live-cell imaging-compatible plate. For improved stability and reproducibility, use patterned FEP foil with small wells to prevent the drops from being washed away during medium changes [55].
• Live-Cell Imaging: Place the plate in a live-cell imaging system (e.g., IncuCyte) equipped with environmental control (37°C, 5% CO₂). Acquire images of both the GFP (caspase activity) and mCherry (cell presence) channels at regular intervals (e.g., every 30-60 minutes) over the desired culture period (e.g., 80-120 hours).
• Validation and Specificity Testing:
  • Induction: Treat organoids with a known apoptosis inducer (e.g., 1-10 µM carfilzomib). A robust, time-dependent increase in GFP fluorescence should be observed [11].
  • Inhibition: Co-treat organoids with the inducer and a pan-caspase inhibitor (e.g., 20-50 µM zVAD-FMK). This should abrogate the GFP signal, confirming the caspase dependence of the reporter activation [11].
• Image and Data Analysis: Use automated analysis software to quantify the GFP and mCherry fluorescence intensity over time. The GFP/mCherry ratio can be used to normalize caspase activation to cell number. A sudden, widespread activation of caspase signals indicates generalized culture stress, while sporadic activation may point to specific sub-populations of dying cells.

Protocol: Establishing a Microglia-Containing Neural Organoid Model

This protocol outlines a method for generating complex neural organoids with integrated microglia, highlighting the importance of controlled cell aggregation for long-term viability and preventing necrosis [56].

Key Reagents:

• hiPSC-derived neural progenitors.
• hiPSC-derived microglia progenitors.
• U-bottom 96-well plates with ultra-low attachment (ULA) surface.
• Neural organoid differentiation medium.

Methodology:

• Cell Aggregation: Aggregate hiPSC-derived neural progenitors and microglia progenitors in a controlled ratio directly in U-bottom 96-well ULA plates. This method allows for the reproducible and standardized formation of organoid structures from the outset, ensuring proper cell-cell interactions and minimizing the core aggregation defects that can lead to hypoxia and necrosis [56].
• Long-term Culture: Maintain the aggregated organoids for extended periods (over 9 weeks). The correct initial aggregation and progenitor ratio support a self-sustaining neural environment where microglia integrate, mature, and survive without the need for costly exogenous microglia-specific growth factors, promoting overall organoid health [56].
• Viability Assessment: At endpoint, assess organoid viability and integrity using assays such as a papain viability assay, immunohistochemistry for glial and neuronal markers, and multi-electrode array (MEA) recordings for functional electrophysiological activity [57] [56].

Signaling Pathways and Experimental Workflows

<100 chars: Cell Death Pathways in Organoids

<100 chars: Real-Time Viability Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for Organoid Health and Caspase Monitoring

Item	Function/Application	Specific Example
Caspase-3/7 Reporter	Real-time, specific visualization of executioner caspase activity in live cells.	ZipGFP-based DEVD biosensor (split-GFP system) [11].
Constitutive Fluorescent Marker	Normalizes for cell presence and transduction efficiency; tracks viable cell number.	Constitutively expressed mCherry [11].
Pan-Caspase Inhibitor	Validates caspase-dependence of cell death observed in experiments.	zVAD-FMK [11].
Stabilized Culture Substrate	Provides a reproducible 3D environment for organoid growth, improving viability during long-term imaging.	Matrigel drops on patterned FEP foil [55].
U-bottom ULA Plates	Enables controlled and reproducible aggregation of multiple progenitor types for complex organoid formation.	96-well ULA plates for neural-microglia organoids [56].

Monitoring caspase activity in 3D organoid cultures is essential for assessing apoptosis in developmental biology, disease modeling, and drug efficacy studies. However, the three-dimensional architecture that makes organoids physiologically relevant also introduces significant technical barriers for high-quality imaging. Key challenges include phototoxicity from prolonged light exposure during live-cell imaging, poor dye penetration into dense organoid cores, and signal heterogeneity that complicates quantitative analysis. This application note details practical protocols and solutions to overcome these pitfalls, enabling more accurate and reproducible caspase activity monitoring in 3D organoid systems.

Mitigating Phototoxicity in Live-Cell Imaging

Understanding the Problem

Phototoxicity occurs when prolonged or high-intensity light exposure during imaging generates reactive oxygen species, causing DNA damage, altered cell physiology, and ultimately, cell death [58]. This is particularly problematic in live-cell caspase activity monitoring, as the imaging process itself can induce apoptosis, creating experimental artifacts and compromising data integrity.

Technical Solutions and Protocols

Minimizing Light Exposure: Implement simultaneous multi-channel acquisition systems like the Leica Mica Microhub with FluoSync technology to capture up to four fluorescent labels in a single acquisition, eliminating sequential imaging and reducing light exposure by up to 75% [58].

Optimized Imaging Systems: Utilize systems with high sensitivity detectors, such as the THUNDER Imager, which employ computational clearing to reduce required light intensity while maintaining signal-to-noise ratio [58].

Environmental Control: Maintain organoids in climate-controlled imaging chambers that regulate temperature, CO₂, and humidity to preserve physiological integrity during extended time-lapse experiments [58].

Table 1: Phototoxicity Mitigation Strategies and Their Impact

Strategy	Implementation	Benefit	System Example
Simultaneous Multi-channel Imaging	Capture multiple fluorescent labels in one acquisition	Reduces light exposure by up to 75%, prevents spatiotemporal mismatches	Leica Mica with FluoSync [58]
Computational Clearing	Algorithm-based background reduction	Allows lower excitation intensity, minimizes photobleaching	THUNDER Imaging System [58]
Environmental Control	Integrated incubation during imaging	Maintains cell viability during long-term caspase monitoring	Climate-controlled chambers [58]

Overcoming Poor Dye Penetration in 3D Structures

The Penetration Barrier

The dense cellular architecture and extracellular matrix in organoids create physical barriers that limit the penetration of caspase activity dyes and probes. This results in superficial signal detection while the core remains unlabeled, potentially missing critical apoptotic events in inner cell layers.

Experimental Protocol: Dye Penetration Assessment

Objective: Systematically evaluate and optimize dye penetration for caspase activity monitoring in 3D organoids.

Materials:

• Patient-derived organoids or 3D spheroids (300-500 µm diameter)
• Cell-penetrating peptides (CPPs) with varying membrane activity
• Caspase activity dyes (e.g., FLICA, CellEvent)
• Confocal microscopy system with environmental control
• Image analysis software (e.g., ImageJ, Imaris)

Procedure:

• Organoid Preparation: Culture organoids to desired size (300-500 µm) using ultra-low attachment (ULA) plates to promote uniform spheroid formation [59].
• Dye Selection and Formulation:
  • Test cationic cell-penetrating peptides (CPPs) with varying membrane activities
  • Consider D-amino acid CPPs for improved stability and prolonged retention
  • Prepare dye-CPP conjugates in serum-free culture medium
• Staining Protocol:
  • Incubate organoids with dye solutions for 2-24 hours at 37°C
  • Include appropriate controls (untreated, apoptosis-induced)
  • Perform gentle agitation during incubation to promote uniform distribution
• Penetration Assessment:
  • Acquire z-stack images using confocal microscopy at multiple time points
  • Quantify fluorescence intensity from periphery to core using line profile analysis
  • Process a subset of organoids for flow cytometry to confirm internalization

Troubleshooting:

• If peripheral sequestration occurs, switch to low membrane-active CPPs
• For rapid signal clearance, implement D-amino acid CPP variants
• If non-specific binding dominates, optimize washing protocols and include competitive inhibitors

Table 2: Dye Penetration Characteristics by CPP Type

CPP Type	Membrane Activity	Penetration Depth	Retention Time	Best Use Case
High Membrane-Active CPPs	High	Shallow (peripheral sequestration)	Short	Rapid screening of surface apoptosis
Low Membrane-Active CPPs	Low	Deep (core penetration)	Prolonged	Comprehensive organoid assessment
D-amino Acid CPPs	Moderate	Intermediate to Deep	Extended	Long-term kinetic studies

Addressing Signal Heterogeneity and Quality Control

Signal heterogeneity in organoid imaging stems from multiple sources, including inherent biological variability, inconsistent organoid quality, and technical imaging artifacts. Recent research has identified that the presence of mesenchymal cells (MC) correlates strongly with organoid quality and morphological features, significantly impacting experimental reproducibility [60].

Protocol: Organoid Quality Control and Standardization

Objective: Establish quantitative criteria for organoid selection to minimize heterogeneity in caspase activity studies.

Materials:

• Brightfield microscope with camera
• Image analysis software (ImageJ with custom macros)
• Organoids at consistent developmental stage (e.g., day 30 for brain organoids)
• Pre-defined quality thresholds

Procedure:

• Image Acquisition: Capture brightfield images of organoids under standardized magnification and lighting conditions.
• Morphological Parameter Measurement:
  • Use ImageJ to measure key parameters: Feret diameter, area, perimeter, cyst presence/area
  • Apply automated thresholding to distinguish organoid from background
  • Export quantitative data for statistical analysis
• Quality Classification:
  • Apply Feret diameter threshold (e.g., 3050 µm for brain organoids) [60]
  • Classify as high-quality: spherical shape with neuroepithelial buds
  • Classify as low-quality: large fluid-filled cysts, irregular shape, migrating cells
• Transcriptomic Validation (Optional):
  • For rigorous quality control, perform bulk RNA sequencing on sample organoids
  • Use BayesPrism deconvolution to estimate mesenchymal cell content [60]
  • Correlate morphological parameters with transcriptional profiles

Quality Control Criteria:

• High-quality organoids: Feret diameter < 3050 µm, low mesenchymal cell content (<10%)
• Low-quality organoids: Feret diameter > 3050 µm, high mesenchymal cell content (>30%)

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents and Tools for 3D Organoid Caspase Imaging

Category	Product/Technology	Key Function	Application Notes
Live-Cell Imaging Systems	Leica Mica Microhub	Simultaneous multi-channel imaging	Reduces phototoxicity by eliminating sequential scanning [58]
Computational Imaging	THUNDER Imaging System	Computational background clearing	Enables lower light exposure while maintaining image clarity [58]
Caspase Detection	Cell-penetrating peptides (CPPs)	Enhanced dye delivery to organoid core	Low membrane-active variants improve penetration depth [61]
Quality Control	Brightfield analysis + Feret diameter	Objective organoid selection	<3050 µm diameter correlates with low mesenchymal cell content [60]
Culture Platform	Ultra-low attachment (ULA) plates	Promote uniform spheroid formation	Essential for reproducible organoid generation [59]
Environmental Control	Climate chamber systems	Maintain viability during imaging	Regulates temperature, CO₂, humidity for long-term studies [58]

Implementing the strategies outlined in this application note—systematic phototoxicity mitigation, optimized dye penetration protocols, and rigorous quality control based on morphological parameters—significantly enhances the reliability of caspase activity monitoring in 3D organoid cultures. The integration of advanced imaging technologies with standardized analytical frameworks addresses the core technical pitfalls that have historically limited quantitative analysis in 3D systems. As organoid technologies continue to evolve, coupling these optimized imaging approaches with emerging methods such as single-cell analysis and organoid-on-chip platforms will further strengthen their application in drug development and personalized therapy optimization.

Within the rapidly advancing field of 3D organoid culture research, accurately monitoring cell death dynamics is crucial for applications in drug development and regenerative medicine. Apoptosis, a programmed cell death mechanism, is primarily executed by a family of cysteine-dependent proteases known as caspases. Among these, caspase-3 and -7 are key effector enzymes responsible for the systematic dismantling of the cell [11]. The ability to specifically confirm that observed phenotypic changes are due to caspase-mediated apoptosis is a fundamental requirement for reliable data interpretation. This application note details the methodology for validating caspase specificity in both 2D and complex 3D organoid systems using pan-caspase inhibitors, with a focus on Z-VAD-FMK (zVAD). As a cell-permeant, irreversible pan-caspase inhibitor, Z-VAD-FMK binds to the catalytic site of caspase proteases, making it an essential tool for control experiments [62] [11].

The Critical Role of Caspase Specificity in 3D Organoid Research

Three-dimensional organoid cultures have emerged as a transformative platform, recapitulating human tissue complexity with greater fidelity than traditional 2D cultures [1] [39]. However, this physiological relevance introduces complexity in assay design and interpretation. When investigating cell death in response to therapeutic compounds or pathophysiological stimuli, researchers must distinguish between caspase-dependent apoptosis and other forms of regulated cell death, such as necroptosis or pyroptosis.

The use of caspase inhibitors like Z-VAD-FMK serves as a critical experimental control to confirm the caspase dependency of an observed cell death phenotype. For instance, in a recent 2025 study utilizing a novel fluorescent reporter for caspase-3/7 activity, co-treatment with zVAD-FMK abrogated the GFP signal induced by pro-apoptotic agents, conclusively demonstrating that the reporter activation was caspase-dependent [11]. Incorporating such specificity controls is especially vital in 3D organoid systems due to their heterogeneous cellular composition and the potential for altered drug penetration and metabolism.

Key Research Reagent Solutions

The table below summarizes essential reagents for conducting caspase inhibition assays in organoid cultures.

Table 1: Essential Reagents for Caspase Specificity Assays

Reagent	Function/Description	Example Application
Z-VAD-FMK (Pan-caspase inhibitor)	Cell-permeant, irreversible inhibitor that binds the catalytic site of most caspases [62].	Served as a critical control to confirm caspase-dependency in a live-cell imaging study [11].
Q-VD-OPh (Pan-caspase inhibitor)	A broad-spectrum caspase inhibitor with enhanced efficacy and reduced toxicity at high concentrations in vivo [63].	An alternative to Z-VAD-FMK, particularly for long-term assays where lower cytotoxicity is desired.
Caspase-3/7 Fluorescent Reporter	Genetically encoded biosensor (e.g., ZipGFP) that fluoresces upon cleavage by caspase-3/7, enabling real-time apoptosis tracking [11].	Enabled dynamic, single-cell resolution tracking of apoptotic events in 2D, 3D spheroids, and patient-derived organoids (PDOs) [11].
Annexin V / Propidium Iodide (PI)	Standard flow cytometry assay for detecting phosphatidylserine externalization (early apoptosis) and loss of membrane integrity (late apoptosis/necrosis) [64].	Used to validate the induction of apoptosis in conjunction with other methods [11].
Antibodies (Cleaved Caspase-3, Cleaved PARP)	Antibody-based methods (Western Blot, IHC) for detecting specific proteolytic cleavage events, hallmark features of caspase activation [64] [65].	Western blot analysis revealed increased levels of cleaved PARP and cleaved caspase-3 following apoptosis induction [11].

Caspase Signaling Pathways and Inhibitor Mechanism

The following diagram illustrates the core apoptotic signaling pathways and the mechanism of pan-caspase inhibitors like Z-VAD-FMK.

Detailed Experimental Protocol for Caspase Inhibition Assay

This protocol is optimized for validating caspase specificity in 3D organoid models, leveraging both real-time fluorescent reporters and endpoint analyses.

Preparation of Reagents and Organoid Cultures

• Z-VAD-FMK Stock Solution: Resuspend the lyophilized powder in molecular biology-grade DMSO to a standard stock concentration of 20 mM [62]. Aliquot and store at -20°C to avoid freeze-thaw cycles.
• Organoid Culture: Maintain patient-derived organoids or cell line-derived spheroids in their appropriate 3D culture matrix (e.g., Cultrex, Matrigel) and culture medium [11] [39]. Ensure organoids are of a consistent size and developmental stage for the assay.

Experimental Treatment and Real-Time Imaging

• Treatment Groups: For a robust validation, include the following conditions in your experiment:
  • Vehicle Control: Culture medium with 0.1-0.2% DMSO (the vehicle for Z-VAD-FMK).
  • Apoptosis Inducer Only: Treatment with your selected cytotoxic agent (e.g., 1-10 µM Carfilzomib [11] or other chemotherapeutics).
  • Inhibitor Control Only: Treatment with 20-50 µM Z-VAD-FMK [64] [11].
  • Co-treatment Group: Pre-treatment with Z-VAD-FMK for 1-2 hours, followed by co-treatment with the apoptosis inducer and Z-VAD-FMK.
• Real-Time Imaging: Transfer the culture plate to a live-cell imaging system. For caspase-3/7 reporter-expressing organoids, acquire images using appropriate GFP (for reporter signal) and RFP/mCherry (for constitutive cell marker) channels every 2-4 hours for 48-96 hours [11].

Table 2: Key Parameters for Live-Cell Imaging Assay

Parameter	Specification	Rationale
Z-VAD-FMK Working Concentration	20 - 50 µM	Effective pan-caspase inhibition based on recent literature [64] [11].
Pre-treatment Time	1 - 2 hours	Allows inhibitor uptake prior to apoptosis induction.
Imaging Interval	2 - 4 hours	Captures kinetic data without excessive phototoxicity.
Assay Duration	48 - 96 hours	Covers the expected timeframe for apoptosis execution in 3D models.

Endpoint Analysis and Validation

Following live-cell imaging, process organoids for complementary endpoint analyses to corroborate the imaging data.

• Flow Cytometry: Dissociate organoids into single-cell suspensions. Stain with Annexin V and Propidium Iodide (PI) according to manufacturer protocols to quantify the percentage of cells in early (Annexin V+/PI-) and late (Annexin V+/PI+) apoptosis [11]. The co-treatment group should show a significant reduction in Annexin V-positive cells compared to the apoptosis inducer-only group.
• Western Blotting: Analyze lysates from pooled organoids for key apoptotic markers:
  • Cleaved Caspase-3: The active form of the key executioner caspase.
  • Cleaved PARP: A classic substrate of executioner caspases [64] [11].
  • β-Actin: Loading control. Successful caspase inhibition by Z-VAD-FMK should markedly reduce or eliminate the bands corresponding to cleaved Caspase-3 and cleaved PARP.

Data Interpretation and Validation Workflow

The flowchart below outlines the logical process for analyzing data and confirming caspase specificity.

Analysis of Expected Results

When the caspase inhibition assay is successfully executed, the data from all modalities should consistently tell the same story.

• Live-Cell Imaging: Organoids treated with the apoptosis inducer alone will show a strong, time-dependent increase in caspase-3/7 reporter fluorescence. This signal should be substantially suppressed in the Z-VAD-FMK co-treatment group, comparable to baseline levels in the vehicle control [11].
• Flow Cytometry: A significant increase in Annexin V-positive cells in the apoptosis-induced group should be abolished or greatly reduced by Z-VAD-FMK co-treatment.
• Western Blot: Bands for cleaved caspase-3 and cleaved PARP should be prominent in the apoptosis-induced group but absent or faint in the Z-VAD-FMK co-treatment group.

The concordance of these orthogonal readouts provides powerful validation that the observed cell death is indeed caspase-dependent apoptosis.

Integrating caspase specificity controls, such as the use of Z-VAD-FMK, is a non-negotiable component of rigorous experimental design in 3D organoid research. The protocol outlined here, combining real-time fluorescent reporters with endpoint validation assays, provides a comprehensive framework for confirming that phenotypic outcomes are driven by caspase-mediated apoptosis. This approach is essential for generating reliable and interpretable data in high-content screening, mechanistic studies of cell death, and the evaluation of novel therapeutics in physiologically relevant organoid models.

The transition from traditional 2D cell culture to physiologically relevant 3D organoid models has created a critical bottleneck in high-throughput screening (HTS). Conventional methods for assessing cell health, such as caspase activity measurement, face significant challenges in 3D environments, including poor reagent penetration, limited spatial resolution, and an inability to capture dynamic, single-cell events within complex tissue structures [11] [13]. This application note details integrated protocols that combine advanced bioreactor systems with automated screening platforms to overcome these limitations, enabling scalable, real-time monitoring of apoptosis in 3D organoid cultures with single-cell resolution. These methodologies are particularly valuable for drug development professionals seeking to characterize therapeutic efficacy and immunogenic cell death (ICD) in models that faithfully recapitulate in vivo biology [11] [66].

The following workflow diagrams illustrate the core processes for automated screening and real-time caspase monitoring.

Automated High-Throughput Screening Workflow

Real-Time Caspase Activity Monitoring Pathway

Quantitative Comparison of Screening Platforms

The selection of an appropriate screening platform depends on throughput requirements, analytical needs, and model complexity. The table below summarizes key performance characteristics.

Table 1: Performance Comparison of High-Throughput Screening Platforms

Platform Feature	Automated Microbioreactor (ambr15)	Digital Colony Picker (DCP)	3D Organoid Caspase Imaging
Working Volume	10-15 mL [67]	Picoliter-scale microchambers [68]	50-200 µL (organoid culture) [11]
Throughput	24-48 parallel bioreactors [67]	16,000 addressable microchambers [68]	96- or 384-well formats [11] [13]
Key Measurements	Online pH, DO, growth, metabolites [67]	Single-cell growth, morphology, metabolic activity [68]	Caspase-3/7 activity, viability, proliferation [11]
Temporal Resolution	Real-time (minutes) [67]	Dynamic monitoring (hours-days) [68]	Real-time (minutes-hours) [11]
Spatial Resolution	Bulk population	Single-cell [68]	Single-cell within organoids [11]
Z´ Factor for HTS	0.67 (demonstrated for 3D caspase assay) [13]	Not specified	0.67 (Caspase-Glo 3/7 3D Assay) [13]

Detailed Experimental Protocols

Protocol: Real-Time Caspase-3/7 Monitoring in 3D Organoids

Principle: This protocol uses a stable fluorescent reporter system (ZipGFP) for real-time, single-cell visualization of caspase-3/7 activity in 3D organoids, enabling dynamic tracking of apoptosis and concomitant proliferation [11].

Materials:

• Stable reporter cell line expressing ZipGFP caspase-3/7 biosensor and constitutive mCherry [11]
• Patient-derived organoids (PDOs) or spheroids [11] [66]
• Apoptosis inducer (e.g., 1-10 µM Carfilzomib) [11]
• Pan-caspase inhibitor control (e.g., 20 µM zVAD-FMK) [11]
• Live-cell imaging compatible microplate (e.g., 96-well) [11]
• Confocal or high-content live-cell imaging system [11] [66]

Procedure:

• Organoid Generation & Transduction: Generate organoids from cell lines or patient-derived samples in Matrigel or other ECM substitutes. For reporter lines, transduce cells with lentiviral vectors carrying the ZipGFP-DEVD-mCherry construct and select stable populations [11] [66].
• Experimental Setup: Plate organoids in a live-cell imaging-compatible microplate. Establish experimental conditions including vehicle control, apoptosis-inducer, and caspase inhibitor control (e.g., 1-hour pre-treatment with zVAD-FMK before inducer) [11].
• Live-Cell Imaging: Place the plate in a controlled environmental chamber (37°C, 5% CO₂) on a confocal or high-content imaging system.
  • Acquire images using a 10x or 20x objective at regular intervals (e.g., every 30-60 minutes) for 48-120 hours [11].
  • ZipGFP Signal (Caspase Activity): Excite at 488 nm, detect emission at 500-550 nm.
  • mCherry Signal (Cell Presence): Excite at 587 nm, detect emission at 610 nm [11].
• Image & Data Analysis: Use automated image analysis software (e.g., Imaris, IncuCyte AI Cell Health Module) to quantify:
  • Apoptotic Index: Number of ZipGFP-positive objects per total mCherry-positive objects over time [11].
  • Viable Cell Count: Automated count of mCherry-positive objects, noting that mCherry's long half-life makes it a lagging indicator of viability loss [11].
  • Apoptosis-Induced Proliferation (AIP): Co-stain with a proliferation dye (e.g., CellTrace) to track division events in non-apoptotic neighbor cells following apoptotic stimuli [11].

Protocol: Automated Phenotypic Screening Using Digital Colony Picking

Principle: The AI-powered Digital Colony Picker (DCP) platform enables high-throughput, contact-free screening and export of microbial or mammalian clones based on growth and metabolic phenotypes at single-cell resolution in picoliter-scale microchambers [68].

Materials:

• Digital Colony Picker platform (microfluidic chip, optical module, laser export) [68]
• Pre-engineered microbial or mammalian cell suspension [68]
• Appropriate growth medium
• Collection plate (e.g., 96-well) [68]

Procedure:

• Chip Preparation & Single-Cell Loading:
  • Pre-vacuum the microfluidic chip to remove air from the 16,000 microchambers.
  • Prepare a single-cell suspension at an optimized concentration (~1×10⁶ cells/mL for 300 pL chambers) to maximize single-cell occupancy (≈30% of chambers) via Poisson distribution [68].
  • Introduce the cell suspension into the chip's main channel. Vacuum-assisted loading will rapidly distribute single cells into microchambers in less than one minute [68].
• Incubation & Phenotypic Monitoring:
  • Place the chip in a humidified chamber (e.g., a 50 mL centrifuge tube with 10% water volume) within a precision incubator to mitigate evaporation (<6% liquid loss over 24 hours) [68].
  • Incubate until individual cells form microscopic monoclonal colonies.
  • Use the integrated AI-driven image analysis to dynamically monitor single-cell morphology, proliferation, and metabolic activities in real-time [68].
• Target Identification & Contact-Free Export:
  • Based on predefined phenotypic criteria (e.g., growth rate, fluorescence), the AI software identifies target microchambers.
  • Inject oil phase into the chip to isolate microchambers.
  • Precisely position a laser focus at the base of identified microchambers. Use Laser-Induced Bubble (LIB) technique to generate microbubbles that propel the single-clone droplet toward the outlet [68].
• Collection & Downstream Analysis:
  • Collect exported monoclonal droplets via a capillary tube into a 96-well collection plate containing recovery medium [68].
  • Expand collected clones for downstream genomic analysis or further phenotypic validation.

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 2: Key Reagents and Materials for High-Throughput Organoid Screening

Item	Function/Application	Example Product/Assay
Caspase-3/7 Reporter	Real-time visualization of apoptosis via DEVD cleavage; minimal background fluorescence [11]	ZipGFP-based biosensor (lentiviral construct) [11]
Homogeneous Caspase Assay	Luminescent, endpoint measurement of caspase-3/7 activity in 3D models; suitable for HTS [13]	Caspase-Glo 3/7 3D Assay [13]
Extracellular Matrix	Provides a 3D scaffold for organoid growth and maturation, mimicking the in vivo microenvironment.	Cultrex, Matrigel [11] [66]
Microfluidic Chip	High-throughput platform for single-cell isolation, cultivation, and phenotypic screening.	DCP Chip (16,000 microchambers) [68]
Automated Microbioreactor	Parallel cultivation with online monitoring and control of process parameters (pH, DO, temperature).	ambr15 system [67]
Proliferation Dye	Tracking cell division in neighboring cells to study apoptosis-induced proliferation.	CellTrace dyes [11]
Immunogenic Marker	Endpoint measurement of immunogenic cell death by flow cytometry.	Anti-Calreticulin antibody [11]

From Model to Clinic: Validating Organoid Caspase Responses Against Patient Outcomes

The transition from pre-clinical models to clinical efficacy remains a significant bottleneck in oncology drug development. This application note details the use of advanced ex vivo models that maintain key characteristics of the native tumor microenvironment (TME) to better predict in vivo therapeutic responses. Focusing on pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), we present quantitative case studies and standardized protocols that demonstrate a strong correlation between ex vivo drug sensitivity and clinical outcomes. These models address the limitations of conventional 2D cultures and patient-derived xenografts (PDXs) by preserving critical aspects such as tumor architecture, cellular heterogeneity, and stromal components [69] [70] [71].

Key Case Studies Demonstrating Correlation

Pancreatic Cancer: Real-Time Live Tissue Sensitivity Assay (RT-LTSA)

A 2023 study developed RT-LTSA using freshly resected PDAC tissue slices to predict adjuvant chemotherapy response. The model preserved tissue viability and TME composition over a 5-day culture period [69].

Table 1: Correlation between RT-LTSA Results and Clinical Outcomes in PDAC

RT-LTSA Result for Adjuvant Regimen	Patients (n)	Recurrence (n)	Median Disease-Free Survival	Statistical Significance
Sensitive	4	0	Not reached	P = 0.02
Resistant	8	7	10.6 months

A significant negative correlation was observed between the RT-LTSA assay value and relapse-free survival (Somer’s D: -0.58; P = 0.016). Furthermore, eight patients who later received RT-LTSA-resistant gemcitabine/nab-paclitaxel for metastatic disease had a median progression-free survival of only 2.0 months [69]. This demonstrates the assay's utility in guiding both adjuvant and palliative treatment decisions.

Colorectal Cancer: Acute Ex Vivo Treatment of Biopsies

A proof-of-concept study utilized fresh CRC biopsies to assess response to the MEK1/2 inhibitor Selumetinib. Tumor fragments were treated ex vivo for less than 6 hours, and response was evaluated through phosphorylated ERK1/2 (pERK1/2) inhibition and Ki-67 proliferation markers [72].

Table 2: Ex Vivo Selumetinib Response in Colorectal Cancer Biopsies

Patient Group	Tumors with Significant Proliferation Decrease	Genotype-Phenotype Association
All Patients (n=23)	5/23 (22%)	Consistent with clinical trial data
KRAS/BRAF Mutant Tumors	Particularly sensitive	Confirmed known mechanism of action

The study successfully identified a subset of responsive tumors and confirmed that tumors with KRAS/BRAF mutations were particularly sensitive to Selumetinib's anti-proliferative effects, aligning with the drug's known mechanism of action [72].

Detailed Experimental Protocols

Protocol 1: RT-LTSA for Pancreatic Cancer

This protocol outlines the procedure for testing chemosensitivity on PDAC tissue slices [69].

• Step 1: Tissue Collection and Processing. Obtain fresh tumor tissue from surgical resection. Immediately place in cold transport medium. Using a vibratome or tissue slicer, generate thin tissue slices (200-300 µm thick) under sterile conditions.
• Step 2: Ex Vivo Culture. Place individual tissue slices in wells of a 96-well plate pre-filled with culture medium. Culture the slices at 37°C with 5% CO2 for the duration of the assay.
• Step 3: Drug Treatment. After a 24-hour stabilization period, treat slices with chemotherapeutic agents of interest (e.g., 5-FU, oxaliplatin, irinotecan) or vehicle control. Include a positive control like auranofin to validate viability assessment.
• Step 4: Viability Assessment. Treat slices for 72 hours. Assess viability on Day 3 using a metabolic assay such as PrestoBlue. Confirm apoptosis via immunohistochemical staining for cleaved-caspase 3.
• Step 5: Data Analysis. Normalize viability readings from drug-treated slices to untreated controls. A significant reduction in viability indicates ex vivo sensitivity. Correlate the sensitivity score with patient outcomes.

Protocol 2: Acute Ex Vivo Treatment of CRC Biopsies

This protocol is designed for rapid drug testing on CRC tissue, generating results within 6 hours [72].

• Step 1: Biopsy Processing. Upon collection, wash the biopsy in PBS. Dissect it into 1-2 mm³ fragments under sterile conditions.
• Step 2: Drug Exposure. Transfer multiple fragments into wells of a 96-well plate. Culture them in medium containing the drug (e.g., 0.1 µM or 3 µM Selumetinib) or vehicle control (DMSO). Incubate at 37°C for 4-6 hours.
• Step 3: Endpoint Analysis.
  • For Pharmacodynamic (PD) Analysis: Homogenize one fragment for protein extraction. Perform Western Blot analysis for pERK1/2 and total ERK1/2 to confirm target engagement.
  • For Phenotypic Response: Fix a second fragment for immunohistochemistry. Stain for Ki-67 to assess proliferation and active caspase-3 to detect apoptosis.
• Step 4: Quantification. Quantify the percentage of Ki-67-positive or active caspase-3-positive epithelial cells in multiple fields of view. A statistically significant decrease in proliferation or increase in apoptosis in drug-treated fragments compared to controls indicates ex vivo sensitivity.

Caspase Activity Monitoring in 3D Cultures

Within the context of 3D organoid culture and caspase activity monitoring, advanced biosensors enable real-time tracking of treatment efficacy. A 2025 study described a fluorescent reporter system for dynamic visualization of caspase-3/-7 activity, key executioner caspases in apoptosis [12].

The system uses a DEVD-based ZipGFP biosensor that is reconstituted into a fluorescent protein upon cleavage by active caspase-3 or -7. This is co-expressed with a constitutive mCherry marker to normalize for cell presence. This platform allows for tracking of apoptotic events at single-cell resolution within complex 3D cultures, providing deeper insights into the kinetics of cell death in response to therapeutics [12].

Caspase Biosensor Pathway

For endpoint analyses in standard organoids, a dye combination of Hoechst 33342 (nuclear stain), Caspase 3/7 Green (for activated caspases), and propidium iodide (for dead cells) can be used in a high-content live-cell imaging pipeline. This allows for segmentation and quantification of individual organoids and the identification of cytotoxic treatment effects [73].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagent Solutions for Ex Vivo and 3D Culture Models

Reagent / Material	Function / Application	Key Considerations
Patient-Derived Tissue	Primary source for ex vivo cultures and organoid generation.	Requires informed consent and ethical approval; viability is time-critical.
Advanced DMEM/F12	Base medium for many ex vivo and organoid culture systems.	Often requires supplementation with growth factors and inhibitors.
Rho-associated kinase (ROCK) inhibitor (Y-27632)	Improves viability of primary cells and stem cells in initial culture.	Typically used for the first few days after plating or passaging.
Matrigel / Synthetic Hydrogels (e.g., Noviogel, PA-ECM)	Provides a 3D scaffold that supports complex tissue architecture and signaling.	Matrigel is undefined; defined synthetic hydrogels (PA-ECM) offer tunability and reproducibility [71].
Caspase-3/7 Activity Reporter (e.g., ZipGFP-DEVD, CellEvent Caspase-3/7 Green)	Detects apoptosis activation in real-time or at endpoint.	ZipGFP provides irreversible, time-accumulating signal for live tracking [12].
Viability Assays (e.g., CellTiter-Glo 3D, PrestoBlue)	Measures metabolic activity as a proxy for cell viability in 3D structures.	Requires validation for specific model; CellTiter-Glo 3D involves lysing samples.
Tumor Slicer / Vibratome	Generates thin, uniform tissue slices for culture while preserving architecture.	Essential for RT-LTSA; slice thickness critical for nutrient diffusion.

The case studies and protocols presented here provide a robust framework for implementing predictive ex vivo models in oncology research. The RT-LTSA for pancreatic cancer and the acute explant model for colorectal cancer successfully bridge the gap between in vitro findings and clinical outcomes by preserving the native TME. Integrating these physiologically relevant models with advanced read-outs, such as real-time caspase imaging, enhances the mechanistic understanding of drug action and resistance. The consistent correlation between ex vivo sensitivity and patient survival across independent studies underscores the potential of these approaches to de-risk drug development and inform personalized treatment strategies.

The pursuit of physiologically relevant pre-clinical models is a central goal in translational cancer research. For decades, patient-derived xenografts (PDX), where human tumor tissue is implanted into immunocompromised mice, have served as a gold standard for pre-clinical modeling, maintaining much of the original tumor's histology and cellular heterogeneity [74] [75]. However, PDX models are constrained by high costs, long engraftment times, ethical considerations, and the absence of a human immune system [74] [76].

The emergence of patient-derived organoids (PDOs)—three-dimensional multicellular structures cultured in vitro from patient tumor tissue—presents a promising alternative. PDOs recapitulate key architectural and molecular features of the original tumor and are more amenable to high-throughput screening [74] [77]. This application note provides a quantitative benchmark of PDO performance against the established gold standards of PDX models and clinical biopsies, with a specific focus on integrating caspase activity monitoring to assess therapeutic response.

Comparative Performance Analysis: PDOs vs. PDXs

A direct comparison of predictive accuracy is essential for establishing the utility of any new model system. A recent systematic review and meta-analysis conducted by Romero et al. (2025) provides the most comprehensive comparative data to date, analyzing 411 patient-model pairs (267 PDX and 144 PDO) from solid tumors where models were treated with identical anti-cancer agents as the matched patient [78] [74].

Table 1: Quantitative Comparison of PDO and PDX Predictive Performance [78] [74]

Performance Metric	PDO Models	PDX Models	Statistical Significance
Overall Concordance	70%	70%	Not Significant (p > 0.05)
Sensitivity	Comparable	Comparable	Not Significant
Specificity	Comparable	Comparable	Not Significant
Positive Predictive Value (PPV)	Comparable	Comparable	Not Significant
Negative Predictive Value (NPV)	Comparable	Not Significant
Association with Patient PFS	Significant prolonged PFS when PDO responded	Association only in low-bias pairs	PDO association more consistent
Typical Establishment Time	Weeks	Months	-
Relative Cost	Lower	Higher	-
Ethical Burden	Lower	Higher (Extensive animal use)	-

The meta-analysis concluded that PDOs perform similarly to PDX models in predicting matched-patient therapeutic response, while offering advantages in terms of speed, cost-effectiveness, and reduced ethical burden [78] [74]. Furthermore, a response in the PDO model was significantly associated with prolonged progression-free survival (PFS) in the matched patient. For PDX, this association was only robust when the analysis was restricted to patient-model pairs with a low risk of bias [74].

Experimental Protocols for Model Establishment and Validation

Protocol: Establishing and Validating Patient-Derived Organoids

Principle: Culture and expand tumor cells from patient samples in a 3D extracellular matrix with defined growth factors to maintain genetic and phenotypic fidelity [77] [75].

Materials:

• Patient Tumor Sample: Freshly collected from surgery or biopsy, placed in cold transport medium.
• Extracellular Matrix: Basement membrane extract (e.g., Matrigel, Cultrex).
• Organoid Culture Medium: Advanced basal medium (e.g., DMEM/F12) supplemented with specific growth factor cocktails (e.g., EGF, Noggin, R-spondin, FGF10), B27, N2, and antibiotics.
• Digestion Enzymes: Collagenase, Dispase, or other tissue-specific dissociation cocktails.
• Tissue Culture Plates: 24-well or 48-well plates for 3D culture.

Procedure:

• Tissue Processing: Mechanically mince the tumor sample into ~1-2 mm³ fragments using scalpel blades. Digest the fragments with an appropriate enzyme mixture (e.g., 2 mg/mL Collagenase) for 30-60 minutes at 37°C with agitation.
• Cell Isolation: Pellet the digested tissue by centrifugation. Resuspend the pellet in organoid culture medium and filter through a 70-100 µm cell strainer to remove debris and large aggregates.
• 3D Embedding: Mix the cell suspension with cold extracellular matrix. Plate 20-50 µL drops of the cell-matrix mixture into pre-warmed tissue culture plates. Allow the drops to solidify for 15-30 minutes in a 37°C incubator.
• Culture Maintenance: Overlay the solidified matrix drops with pre-warmed organoid culture medium. Refresh the medium every 2-3 days.
• Passaging: For expansion, passage organoids every 1-3 weeks. Dissociate organoids by removing the matrix with cold medium or a dissociation reagent, then mechanically or enzymatically break them into small clusters for re-embedding.
• Validation:
  • Genomics: Perform whole-exome or targeted sequencing to confirm fidelity of driver mutations.
  • Histology: Process organoids for immunohistochemistry (IHC) and compare to the original tumor for key markers (e.g., Cytokeratin, ER, HER2 for breast cancer) [75].
  • Drug Screening: Treat organoids with a panel of anti-cancer agents and quantify response via cell viability assays (e.g., CellTiter-Glo 3D).

Protocol: Real-Time Caspase-3/7 Activity Monitoring in Organoids

Principle: Stably express a fluorescent caspase-3/7 biosensor in organoids to dynamically track apoptosis in response to therapeutic agents at single-cell resolution within a 3D structure [12].

Materials:

• Caspase Reporter Construct: Lentiviral vector encoding a ZipGFP-based DEVD caspase-3/7 biosensor and a constitutive fluorescent marker (e.g., mCherry) for normalization [12].
• Polybrene: To enhance viral transduction efficiency.
• Selection Antibiotic: e.g., Puromycin, for selecting stably transduced cells.
• Live-Cell Imaging System: Confocal microscope or high-content imaging system with environmental control (37°C, 5% CO₂).
• Apoptosis Inducers: e.g., Carfilzomib, Oxaliplatin.
• Caspase Inhibitor: e.g., zVAD-FMK, for control experiments.

Procedure:

• Generate Stable Reporter Organoids:
  • Dissociate established organoids into single cells or small clusters.
  • Transduce cells with the lentiviral caspase reporter in the presence of 4-8 µg/mL Polybrene.
  • 48 hours post-transduction, begin selection with the appropriate antibiotic (e.g., 1-2 µg/mL Puromycin) for 5-7 days to establish a stable polyclonal population.
  • Re-embed selected cells in matrix to regenerate reporter-expressing organoids.

• Live-Cell Imaging and Drug Treatment:

  • Plate reporter organoids in a 96-well imaging plate.
  • Treat organoids with the therapeutic agent of interest. Include a negative control (DMSO) and a positive control (e.g., 1 µM Staurosporine).
  • For specificity controls, co-treat with 20 µM pan-caspase inhibitor zVAD-FMK.
  • Immediately place the plate in the live-cell imaging system. Acquire images in both the GFP (caspase activity) and mCherry (cell presence) channels every 2-4 hours for the duration of the experiment (e.g., 72-120 hours).

• Data Analysis:

  • Use image analysis software to quantify the GFP/mCherry fluorescence intensity ratio over time for each organoid.
  • Identify and count apoptotic events (sudden increase in GFP signal) [12].
  • Generate kinetic curves of caspase activation and calculate metrics like time to 50% maximal apoptosis (ET₅₀).

Case Study: Integrated PDX/PDO Platform in Breast Cancer

A landmark study demonstrated the practical synergy between PDX and PDO models in a functional precision oncology setting [75]. Researchers established a biobank of PDX models from aggressive breast cancers, including treatment-resistant and metastatic cases. They then generated matched PDX-derived organoids (PDxOs) from these xenografts.

• Concordance: Drug response testing in the PDxOs showed high concordance with the responses in the matched PDX models in vivo [75].
• Clinical Application: In a case of triple-negative breast cancer (TNBC) with early metastatic recurrence, the team used the matched PDX/PDxO platform for rapid drug screening. This approach identified an FDA-approved drug with high efficacy in the models. The patient was treated with this therapy, achieving a complete response and a progression-free survival period more than three times longer than with previous therapies [75]. This case highlights how PDOs can be leveraged for cost-effective, high-throughput screening, with subsequent validation in PDX models, to directly inform clinical decision-making.

Table 2: Key Research Reagent Solutions for Organoid Caspase Monitoring

Item	Function/Application	Example Product/Specification
Caspase-3/7 Reporter	Lentiviral construct for stable expression of ZipGFP-DEVD biosensor and constitutive mCherry [12].	Custom lentiviral vector (e.g., pLV-ZipGFP-DEVD-mCherry).
Basement Membrane Matrix	Provides a 3D scaffold for organoid growth and differentiation.	Matrigel (Corning), Cultrex BME (R&D Systems).
Organoid Media Kits	Defined, serum-free media tailored to specific tissue types.	IntestiCult (StemCell Tech.), mTeSR for PSCs.
Live-Cell Dyes	For multiplexed endpoint assays (e.g., cell viability, cytotoxicity).	CellTiter-Glo 3D (Viability), PI/Cytoxicity Dyes.
Automated Imaging System	For long-term, high-content live-cell imaging of 3D models.	IncuCyte (Sartorius), ImageXpress Confocal (Molecular Devices).
Caspase Inhibitors	Essential control for confirming caspase-specific reporter activation.	zVAD-FMK (pan-caspase inhibitor), DEVD-CHO (caspase-3/7 inhibitor).

Advanced Workflow: Automation and High-Throughput Screening

To overcome challenges of organoid heterogeneity and scalability, fully automated workflows have been developed. Renner et al. described a robotic system for the generation, maintenance, and analysis of human midbrain organoids in standard 96-well plates [79] [46].

• Key Features: The workflow uses an automated liquid handling system for all steps, from seeding to whole-mount immunostaining and high-content imaging.
• Outcomes: This automation produced organoids with highly homogeneous morphology, size, and cellular composition (average coefficient of variation for size: 3.56%), making them ideal for high-throughput screening (HTS) [79]. Such automated pipelines are directly transferable to cancer PDOs, enabling large-scale, reproducible drug and caspase activity screens.

The collective evidence demonstrates that patient-derived organoids have matured into a model system that matches the predictive accuracy of the long-standing PDX gold standard for evaluating cancer therapy response. Their performance, characterized by 70% overall concordance with patient response, combined with advantages in throughput, cost, and scalability, positions PDOs as a powerful tool for modern cancer research and drug development [78] [74].

The integration of dynamic, real-time caspase activity monitoring within PDOs provides a deeper, mechanistic understanding of treatment-induced apoptosis, moving beyond simple endpoint viability measures. For a comprehensive research program, an integrated strategy is recommended: using PDOs for high-throughput discovery and mechanistic dissection, and employing PDX models for subsequent in vivo validation, creating a synergistic pipeline that accelerates the translation of discoveries from the bench to the clinic.

Regulated cell death, particularly apoptosis executed by caspases, has traditionally been studied in isolation from the complex tumor microenvironment. However, emerging research reveals intricate crosstalk between apoptotic signaling and stromal activation that significantly influences tumor progression, therapeutic resistance, and immune modulation. This application note provides integrated protocols for simultaneously monitoring caspase dynamics and stromal modulation markers in physiologically relevant 3D organoid models, enabling researchers to capture the complex interplay between cell death pathways and tumor-stroma interactions. By combining real-time caspase imaging with endpoint stromal characterization, these methods support more comprehensive therapeutic evaluation in drug discovery pipelines.

Integrated Caspase-Stroma Signaling Networks

Molecular Interplay in the Tumor Microenvironment

The signaling pathways connecting caspase activity to stromal modulation involve complex feedback mechanisms that can be visualized through the following molecular relationship map:

This diagram illustrates the key molecular relationships between caspase activation and stromal responses, highlighting how caspase-8 contributes to immunogenic cell death through calreticulin exposure [80], while caspase-3/7 executioner activity marks apoptotic progression [81]. These caspase-mediated events occur within a cytokine-rich milieu shaped by activated stromal components.

Quantitative Caspase and Stromal Marker Data Integration

Experimental Readouts for Integrated Analysis

Table 1: Key Parameters for Caspase-Stroma Integration Studies

Parameter Category	Specific Measurement	Detection Method	Biological Significance
Caspase Activity	Caspase-3/7 activation kinetics	Live-cell ZipGFP reporter [81]	Timing and extent of apoptotic execution
	Cleaved caspase-3	Flow cytometry [82]	Confirmatory endpoint apoptosis measurement
	Caspase-8 functionality	CRISPR knockout models [80]	Initiation of apoptosis/immunogenic signaling
Stromal Markers	α-SMA expression	Immunofluorescence [83] [84]	Myofibroblastic CAF activation
	CK-19 expression	Immunofluorescence	Biliary/epithelial integrity
	α-SMA/CK-19 ratio	Quantitative image analysis	Stromal-epithelial balance
Immunogenic Cell Death	Surface calreticulin	Flow cytometry [81] [80]	"Eat me" signal for immune activation
Cytokine Signaling	IL-6, CSF-1, LIF	ELISA, proteomics [85] [83] [84]	Stromal-tumor communication

Table 2: Therapeutic Modulation of Caspase-Stroma Axis

Therapeutic Agent	Primary Target	Effect on Caspase Activity	Impact on Stromal Markers	Reference
Carfilzomib	Proteasome	Induces caspase-3/7 activation [81]	Not directly measured	[81]
SOM230	sst1 receptor on CAFs	Indirect via stromal modulation	Reduces CSF-1 production; decreases CAF activation [85]	[85]
Entinostat	Class I HDACs in CAFs	Not directly measured	Suppresses α-SMA, Ki67; reduces stromal activation [84]	[84]
Tocilizumab	IL-6R on tumor cells	Enhances gemcitabine-induced apoptosis	Disrupts CAF-CCA interactions; increases drug sensitivity [83]	[83]
Z-IETD-FMK	Caspase-8 inhibitor	Blocks caspase-8 activity	Impairs calreticulin exposure; reduces immunogenicity [80]	[80]

Experimental Workflows for Integrated Analysis

Comprehensive Protocol for 3D Caspase-Stroma Monitoring

The following workflow diagram outlines the integrated experimental approach for simultaneous caspase dynamics and stromal modulation analysis:

Detailed Protocol Components

3D Model Establishment with Fluorescent Reporters

Materials:

• Low-adhesion plates (e.g., Nunclon Sphera [5] [86]) for spheroid formation
• Matrigel/Cultrex for dome-based organoid culture [87]
• ZipGFP caspase-3/7 reporter construct with constitutive mCherry [81]
• Lentiviral delivery system for stable reporter expression

Procedure:

• Generate spheroids in low-adhesion plates (5,000-10,000 cells/well) or embed cells in Matrigel domes (40-50μL) for organoid culture [5]
• Establish stable reporter lines via lentiviral transduction followed by antibiotic selection
• Validate reporter functionality via carfilzomib treatment (positive control) and zVAD-FMK co-treatment (negative control) [81]
• Culture for 5-7 days with media changes every 48 hours until mature structures form

Real-time Caspase-3/7 Dynamics Monitoring

Materials:

• Live-cell imaging system with environmental control (e.g., IncuCyte or ImageXpress Confocal HT.ai [81] [87])
• ZipGFP caspase-3/7 reporter with DEVD cleavage motif [81]
• Therapeutic compounds of interest + appropriate controls

Procedure:

• Plate reporter-labeled 3D models in optical-bottom plates compatible with high-content imaging
• Acquire baseline images (mCherry + ZipGFP channels) prior to treatment
• Administer therapeutic compounds and initiate time-lapse imaging
• Capture images every 2-4 hours for 72-120 hours maintaining 37°C, 5% CO₂
• Quantify GFP/mCherry fluorescence ratio to normalize caspase activation to cell presence [81]

Endpoint Stromal Marker Analysis

Materials:

• Fixation solution: 4% paraformaldehyde [5]
• Permeabilization buffer: CytoVista Antibody Penetration Buffer or equivalent [5]
• Primary antibodies: Anti-α-SMA (CAF marker), anti-CK-19 (epithelial marker), anti-calreticulin (ICD marker) [80] [83]
• Secondary antibodies: Fluorophore-conjugated with minimal spectral overlap
• Counterstains: DAPI (nuclear) [5]
• Mounting medium: SlowFade Glass Soft-set Antifade Mountant [5]

Procedure:

• Fix spheroids/organoids with 4% PFA for 1 hour at room temperature with gentle agitation
• Permeabilize with penetration buffer for 15 minutes
• Block with species-appropriate blocking buffer for 2 hours at 37°C
• Incubate with primary antibody cocktails overnight at room temperature
• Wash 3× with wash buffer, centrifuging at 500g between washes
• Incubate with secondary antibodies overnight at room temperature
• Counterstain with DAPI (300nM) for 30 minutes
• Wash 3× and mount with antifade mounting medium
• Image using confocal microscopy with Z-stack acquisition

Image Analysis and Data Integration

Quantitative Measures:

• Caspase activation kinetics: Time to 50% maximal GFP signal, rate of signal accumulation
• Spatial heterogeneity: Core vs. periphery caspase activation patterns
• α-SMA/CK-19 ratios: Segment regions of interest and calculate fluorescence intensity ratios
• Calreticulin exposure: Percentage of cells with surface expression >2× background
• Correlative analysis: Map spatial relationships between caspase-active zones and stromal activation

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for Integrated Caspase-Stroma Research

Reagent Category	Specific Product	Application	Experimental Notes
Caspase Reporters	ZipGFP caspase-3/7 DEVD biosensor [81]	Real-time apoptosis imaging	Minimal background, irreversible activation
	CellEvent Caspase-3/7 Green reagent [5]	Endpoint caspase detection	Fixable, compatible with antibody staining
Viability Indicators	LIVE/DEAD Viability/Cytotoxicity Kit [5]	Membrane integrity assessment	Perform before fixation
	mCherry constitutive marker [81]	Cell presence normalization	Long half-life limits real-time viability use
Stromal Antibodies	Anti-α-SMA [83] [84]	Myofibroblastic CAF detection	Key marker for stromal activation
	Anti-CK-19	Biliary/epithelial marker	Countermarker for α-SMA ratio calculations
	Anti-calreticulin [80]	Immunogenic cell death detection	Surface staining requires non-permeabilized conditions
3D Culture Systems	Nunclon Sphera plates [5] [86]	Spheroid formation	Promote self-aggregation
	Matrigel/Cultrex [87]	Organoid scaffolding	Dome formation for structured growth
Therapeutic Modulators	SOM230 (Pasireotide) [85]	CAF sst1 receptor targeting	Reduces CSF-1 production
	Entinostat [84]	Class I HDAC inhibition	Stromal reprogramming
	Tocilizumab [83]	IL-6R blockade	Disrupts CAF-tumor interactions

Applications in Therapeutic Development

Assessing Stromal Modulation of Drug Efficacy

The integrated caspase-stroma platform enables evaluation of how stromal components influence therapeutic efficacy. For example:

Gemcitabine Resistance Modeling:

• CAFs promote cholangiocarcinoma cell viability and gemcitabine resistance via IL-6/STAT3 signaling [83]
• Co-culture CCA cells with CAFs in 3D models and monitor caspase activation post-gemcitabine treatment
• IL-6R blockade with tocilizumab enhances gemcitabine-induced caspase activation [83]

HDAC Inhibition Stromal Targeting:

• Class I HDACs facilitate pro-desmoplastic programs in pancreatic stellate cells [84]
• Entinostat treatment suppresses α-SMA and proliferation markers in CAFs
• Evaluate compartment-specific responses (tumor vs. stromal) using cell-type-specific reporters

Immunogenic Cell Death Assessment

Beyond traditional apoptosis, evaluate immunogenic potential through coordinated detection:

• Monitor caspase-8 activity and subsequent calreticulin exposure [80]
• Correlate caspase activation dynamics with surface calreticulin expression
• Assess pharmacological disruption of immunogenicity (e.g., Z-IETD-FMK impairment of calreticulin exposure [80])

The integration of real-time caspase monitoring with stromal marker analysis in 3D models provides a sophisticated platform for evaluating complex tumor microenvironment interactions. These protocols enable researchers to move beyond simplistic apoptosis assessment to capture the dynamic interplay between cell death execution and stromal modulation, offering enhanced predictive value for therapeutic development. By implementing these integrated approaches, drug discovery programs can better identify compounds that simultaneously target tumor cells and modulate the supportive stroma, potentially overcoming key resistance mechanisms in challenging malignancies like pancreatic ductal adenocarcinoma and cholangiocarcinoma.

A significant challenge in clinical oncology is the variability in patient responses to chemotherapy. The field of preclinical research is being transformed by patient-derived tumor organoids (PDTOs), which recapitulate the histological and molecular characteristics of original tumors [88]. Within these models, caspase activity serves as a central executioner of apoptosis, providing a quantifiable measure of treatment-induced cell death.

This Application Note details how monitoring caspase activation in organoids can predict patient survival and chemotherapy efficacy. We provide validated protocols and analytical frameworks to bridge the gap between in vitro organoid drug response and clinical outcomes, enabling more accurate personalized treatment strategies and drug development.

Quantitative Evidence: Linking Caspase Activation to Survival and Drug Response

Empirical data from recent studies provide a compelling link between caspase activity in organoids, patient survival, and responses to chemotherapy.

• Table 1: Caspase-8 Expression and Patient Survival in DLBCL A clinical study in Diffuse Large B-Cell Lymphoma (DLBCL) directly connected caspase levels to patient outcomes [89].

Caspase-8 Expression Level	Overall Survival	Progression-Free Survival	Hazard Risk	p-value
High	Favorable	Favorable	0.3	0.005
Low	Unfavorable	Unfavorable	-	-

• Table 2: Organoid Caspase-3 Activity as a Biomarker for Therapy Efficacy Caspase-3 activation in organoids, detected via immunohistochemistry, serves as a sensitive marker for drug efficacy across multiple cancer types [66] [90] [91].

Cancer Type	Treatment	Readout	Correlation with Patient Outcome
Merkel Cell Carcinoma	Cisplatin + Doxorubicin	Caspase-3 IHC Staining	Induction of apoptosis in responsive organoid sets [90]
Colorectal Cancer (CRC)	Chemoradiotherapy (BRAF*mutant)	Cleaved Caspase-3 Staining	Increased apoptosis; validated in PDX models [91]
Pancreatic Ductal Adenocarcinoma (PDAC)	Standard-of-Care Chemotherapy	Annexin A5 / Apoptosis Quantification	Associated with tumor volume reduction [66]

Experimental Protocols for Caspase Activity Monitoring in Organoids

Protocol 1: Luminescent Caspase-3/7 Activity Assay

The Caspase-Glo 3/7 3D Assay is a homogeneous, add-mix-measure system designed for high-throughput screening of apoptosis in 3D models [13].

• Key Principle: The reagent lyses cells, and caspase-3/7 cleaves a luminogenic substrate, generating a luminescent signal proportional to caspase activity.
• Advantages: No washing or medium removal required; compatible with tight (spheroids) and loose (Matrigel-embedded) 3D structures; easily multiplexed with viability/cytotoxicity assays.

Procedure:

• Plate Organoids: Seed organoids in a white-walled, clear-bottom 96- or 384-well plate.
• Apply Reagent: Equilibrate Caspase-Glo 3/7 3D Reagent to room temperature. Add an equal volume of reagent to each well (e.g., 100 µL reagent to 100 µL organoid culture medium).
• Mix and Incubate: Mix contents gently using a plate shaker for 30 seconds. Incubate at room temperature for 1-3 hours to stabilize the luminescent signal.
• Measure: Record luminescence using a plate reader.

Protocol 2: Real-Time Imaging of Caspase-3/7 Dynamics

A stable fluorescent reporter system enables live-cell tracking of caspase activation at single-cell resolution within complex 3D organoids [11].

• Key Principle: A lentiviral-delivered biosensor (ZipGFP) contains a caspase-3/7-specific DEVD cleavage motif. Caspase activation causes GFP reconstitution and irreversible fluorescence.
• Advantages: Allows dynamic, asynchronous tracking of apoptosis; co-expression of constitutive mCherry normalizes for cell presence.

Procedure:

• Generate Reporter Organoids: Transduce organoids with a lentiviral vector carrying the DEVD-ZipGFP and mCherry constructs to create a stable cell line.
• Image Acquisition: Plate reporter organoids in glass-bottom dishes and treat with therapeutics. Use a confocal microscope for time-lapse imaging over 48-120 hours.
• Image Analysis: Quantify GFP and mCherry fluorescence intensity over time. Calculate the GFP/mCherry ratio to determine the kinetics of caspase activation.

Protocol 3: Immunohistochemical Analysis of Cleaved Caspase-3

Endpoint analysis of cleaved caspase-3 provides a spatially resolved measure of apoptosis, preserving organoid morphology [91].

Procedure:

• Fix and Embed: Collect organoids after drug treatment, fix in 4% paraformaldehyde, and embed in paraffin blocks.
• Section and Stain: Cut 4 µm sections. Perform antigen retrieval and incubate with a primary antibody against cleaved caspase-3.
• Visualize and Quantify: Use a compatible secondary antibody and chromogen for detection. Counterstain with hematoxylin. Quantify the percentage of cleaved caspase-3-positive cells manually or via digital image analysis software.

Signaling Pathways and Workflows

Apoptosis Signaling Pathway in Cancer Therapy

The following diagram illustrates the core apoptosis pathway and key regulatory nodes that influence caspase activation and therapy response, as identified in the cited research [89] [92].

Experimental Workflow: From Patient Tumor to Clinical Prediction

This workflow outlines the standardized pipeline for using patient-derived organoids to predict chemotherapy response and patient survival based on caspase activity [66] [88] [90].

The Scientist's Toolkit: Essential Research Reagents

Successful implementation of these protocols requires specific reagents and tools. The following table lists key solutions for monitoring caspase activity and viability in organoid models [11] [66] [13].

• Table 3: Key Reagents for Organoid Apoptosis and Viability Analysis

Reagent / Tool Name	Provider/Example	Function / Application
Caspase-Glo 3/7 3D Assay	Promega (G8981)	Homogeneous, luminescent measurement of caspase-3/7 activity in 3D models; ideal for HTS [13].
ZipGFP-based Caspase-3/7 Reporter	Custom Lentiviral Vector	Stable fluorescent reporter for real-time, single-cell visualization of caspase dynamics in live organoids [11].
CellTiter-Glo 3D Cell Viability Assay	Promega (G9681)	Luminescent assay to quantify ATP levels, determining the number of viable cells in 3D cultures. Can be multiplexed with caspase assays [91].
Anti-Cleaved Caspase-3 Antibody	Multiple Providers (CST, etc.)	Immunohistochemical validation of apoptosis endpoint in fixed organoid sections [91].
Annexin A5 Conjugates	Multiple Providers	Binds to phosphatidylserine exposed on the cell surface during early apoptosis; used for flow cytometry or imaging [66].
Extracellular Matrix (ECM) Hydrogel	Corning Matrigel, BME, Collagen-based	Provides a 3D scaffold supporting organoid growth, structure, and signaling [88].

Integrating caspase activity monitoring in patient-derived organoids provides a powerful, quantitative bridge between preclinical drug testing and clinical patient outcomes. The protocols and evidence presented herein establish a robust framework for employing organoids to predict chemotherapy efficacy, understand resistance mechanisms, and ultimately guide personalized oncology, moving beyond traditional models towards a more predictive and patient-specific approach in cancer research and therapy development.

Within the context of 3D organoid culture and caspase activity monitoring research, discerning the specific mode of cell death is paramount for accurate biological interpretation. Apoptosis and necroptosis represent two distinct forms of regulated cell death with fundamentally different implications for tissue homeostasis, disease pathogenesis, and therapeutic outcomes [93]. While apoptosis is a caspase-dependent, immunologically silent process, necroptosis is a lytic, pro-inflammatory pathway [93] [94]. This application note provides a detailed comparative analysis of these pathways and offers robust protocols for their differentiation in complex 3D organoid models, which more closely mimic in vivo physiology than traditional 2D cultures [45] [11].

Background: Key Cell Death Pathways

Molecular Mechanisms of Apoptosis and Necroptosis

Apoptosis can be triggered through intrinsic (mitochondrial) or extrinsic (death receptor) pathways, culminating in the activation of executioner caspases, primarily caspase-3 [65]. This cascade leads to controlled cellular dismantling without inflammatory cytokine release [93]. In contrast, necroptosis occurs when caspase-8 is inhibited, leading to RIPK1 and RIPK3 activation and phosphorylation of MLKL, which forms pores in the plasma membrane, causing lytic cell death and DAMP release [93] [94].

The following diagram illustrates the key regulatory nodes and molecular interactions in these pathways:

Comparative Characteristics of Cell Death Modalities

Table 1: Key characteristics of apoptosis versus necroptosis

Feature	Apoptosis	Necroptosis
Triggers	Death receptor activation, DNA damage, developmental cues	Death receptor activation when caspase-8 is inhibited, TLR activation, viral infection [93] [94]
Key Proteins	Caspase family (esp. caspase-3), CAD, PARP	RIPK1, RIPK3, MLKL, CYLD [94]
Morphological Features	Cell rounding, membrane blebbing, formation of apoptotic bodies, chromatin condensation	Organelle swelling, plasma membrane rupture, release of intracellular contents [94]
Inflammatory Response	No (immunologically silent)	Yes (release of DAMPs and pro-inflammatory mediators) [93]
Fate of Dead Cell	Phagocytosed by neighboring cells	Lysed and cleared by professional phagocytes [93]

Assay Platforms for Cell Death Discrimination

The RIP3-Caspase3 Assay for Spheroid Cultures

A novel RIP3-caspase3-assay has been developed specifically for heterogeneous spheroid cultures, enabling simultaneous analysis of both apoptotic and necroptotic pathways in a single assay [45]. This approach uses directly conjugated monoclonal antibodies to differentiate between RIP1-independent apoptosis, necroptosis, and RIP1-dependent apoptosis, marking a significant advancement for organoid research [45]. The assay is particularly valuable for evaluating TNFα-induced cell death, where researchers have observed a concentration-dependent response with a preference for RIP1-independent pathways upon TNFα stimulation [45].

Real-Time Caspase Activity Monitoring

Fluorescent reporter systems enable real-time visualization of caspase-3/7 activity in living organoids using DEVD-based biosensors [11]. These platforms typically employ a split-GFP architecture where caspase cleavage removes a structural constraint, allowing GFP reconstitution and fluorescence recovery [11]. This system provides irreversible, time-accumulating signals that mark apoptotic events at single-cell resolution within complex 3D structures, overcoming limitations of endpoint assays [11].

The following workflow illustrates the integration of these assays in a comprehensive analysis strategy:

Comparative Assay Methodologies

Table 2: Key assays for discriminating apoptosis from necroptosis

Assay Type	Target/Marker	Apoptosis Readout	Necroptosis Readout	Notes and Considerations
RIP3-Caspase3 Assay [45]	RIP3 and activated caspase-3	Caspase-3 positive, RIP3 negative	RIP3 positive, caspase-3 positive or negative	Enables differentiation of RIP1-independent apoptosis, necroptosis, and RIP1-dependent apoptosis in heterogenous spheroid cultures
Phospho-MLKL Detection [94]	MLKL phosphorylation at Thr357/Ser358	Not applicable	Positive phospho-MLKL signal	Most reliable method for detecting necroptosis; can be used in western blot, IHC, and flow cytometry
Caspase-3/7 Activity [11] [5]	Caspase-3/7 cleavage of DEVD sequence	Positive caspase-3/7 activity	No caspase-3/7 activity (except when apoptosis coexists)	Real-time reporters available for live-cell imaging; specific inhibitors confirm caspase dependence
MLKL Membrane Translocation [93]	MLKL oligomerization and membrane localization	Not applicable	MLKL puncta at plasma membrane	Can be visualized by immunofluorescence; indicates late stage necroptosis commitment
Pathway Inhibition [94]	RIPK1 (Nec-1s), RIPK3 (GSK'872), pan-caspase (zVAD-fmk)	Inhibited by zVAD-fmk	Inhibited by Nec-1s or GSK'872	Use specific inhibitors; Nec-1s has fewer off-target effects than original Nec-1; confirm with genetic models when possible

Detailed Experimental Protocols

RIP3-Caspase3 Assay for 3D Organoids

Principle: This protocol uses directly conjugated monoclonal antibodies against RIP3 and activated caspase-3 to simultaneously evaluate necroptotic and apoptotic signaling in intestinal organoids, adapted from Schwarz et al. [45].

Materials:

• Intestinal organoids cultured in Matrigel domes for 5-7 days
• RIP3 and cleaved caspase-3 directly conjugated antibodies
• CytoVista 3D Cell Culture Clearing/Staining Kit (Thermo Fisher) [5]
• IntestiCult Organoid Differentiation Medium (StemCell Technologies) [45]
• Recombinant TNFα (e.g., PeproTech #300-01A) [45]

Procedure:

• Organoid Differentiation: Culture organoids in OGM-h for 5 days, then switch to differentiation medium (ODM-h) supplemented with 5 mM DAPT for 3-5 days until bud-like structures form [45].
• TNFα Treatment: Treat organoids with TNFα (0.1-100 ng/mL) in ODM-h for 72 hours, with one medium change at 36 hours [45].
• Sample Processing:
  • Remove medium and break up Matrigel domes with Advanced DMEM
  • Centrifuge at 500×g for 5 min at 4°C
  • Dissociate organoids with TrypLE at 37°C for 4 min to generate single cells [45]
• Fixation and Permeabilization:
  • Fix cells with 4% paraformaldehyde for 1 hour at room temperature
  • Permeabilize with CytoVista Antibody Penetration Buffer for 15 min [5]
  • Block with CytoVista Blocking Buffer for 2 hours at 37°C [5]
• Antibody Staining:
  • Incubate with directly conjugated anti-RIP3 and anti-cleaved caspase-3 antibodies prepared in CytoVista Antibody Dilution Buffer overnight at room temperature [45] [5]
  • Wash 3× with CytoVista Wash Buffer
• Analysis: Assess by flow cytometry or image using a microscope with Z-stack capabilities and 2D/3D deconvolution software [5].

Interpretation: Caspase-3+/RIP3- cells indicate apoptosis; Caspase-3-/RIP3+ cells indicate necroptosis; Caspase-3+/RIP3+ cells may indicate overlapping regulation [45].

Real-Time Caspase-3/7 Monitoring in Live Organoids

Principle: This protocol uses a stable fluorescent reporter system to track caspase-3/7 activation dynamics in living organoids, adapted from methods described by researchers using ZipGFP-based DEVD biosensors [11].

Materials:

• Organoids transduced with lentiviral ZipGFP caspase-3/7 reporter and constitutive mCherry marker
• CellEvent Caspase-3/7 Green Detection Reagent (Thermo Fisher) [5]
• Apoptosis inducer (e.g., carfilzomib, oxaliplatin)
• Pan-caspase inhibitor (zVAD-FMK) for control
• Live-cell imaging compatible plate (e.g., Glass-bottom 96-well plates)

Procedure:

• Baseline Imaging: Plate reporter organoids in Matrigel in glass-bottom plates and acquire baseline GFP and mCherry images.
• Treatment: Add apoptosis inducer with or without 20 µM zVAD-FMK pre-treatment [11].
• Live-Cell Imaging:
  • Maintain organoids at 37°C with 5% CO₂ during imaging
  • Acquire images every 2-4 hours for up to 120 hours
  • Use consistent exposure settings across experiments [11]
• Alternative Chemical Detection:
  • For non-reporter organoids, add CellEvent Caspase-3/7 Green reagent diluted 1:1000 in PBS with 2 µM final concentration
  • Incubate for 30-60 minutes at 37°C protected from light [5]
  • Image using standard FITC filter sets
• Image Analysis: Quantify GFP/mCherry ratio over time or count caspase-3/7 positive cells using high-content analysis software.

Interpretation: Progressive increase in GFP signal indicates caspase-3/7 activation; suppression by zVAD-FMK confirms caspase dependence; mCherry provides cell presence normalization [11].

Necroptosis Verification via Phospho-MLKL Staining

Principle: This protocol confirms necroptosis by detecting phosphorylated MLKL, the terminal effector in necroptosis, using phospho-specific antibodies [94].

Materials:

• Anti-MLKL (phospho S358) antibody [94]
• RIPK1 inhibitor (Nec-1s) and RIPK3 inhibitor (GSK'872) [94]
• Standard immunofluorescence reagents

Procedure:

• Treatment: Incubate organoids with cell death inducers with or without necroptosis inhibitors (10 µM Nec-1s or 1 µM GSK'872) [94].
• Fixation and Staining: Follow standard immunofluorescence protocol with the following modifications:
  • Use cold methanol fixation for better phospho-epitope preservation
  • Incubate with anti-phospho-MLKL antibody (1:250-1:1000 dilution) overnight at 4°C [94]
• Image Analysis: Evaluate phospho-MLKL localization; membrane translocation indicates active necroptosis.

Interpretation: Phospho-MLKL signal inhibited by Nec-1s or GSK'872 confirms necroptosis specificity [94].

Research Reagent Solutions

Table 3: Essential reagents for cell death pathway analysis

Reagent/Category	Specific Examples	Primary Function	Application Notes
3D Culture Systems	Corning Matrigel Matrix [45]	Provides basement membrane matrix for organoid growth	Use growth factor-reduced, phenol red-free for fluorescence assays
Caspase Detection	CellEvent Caspase-3/7 Green [5]	Fluorogenic substrate for caspase-3/7 activity	Fixable dye allows subsequent antibody staining
Viability Assays	LIVE/DEAD Viability/Cytotoxicity Kit [5]	Simultaneously labels live (calcein-AM) and dead (EthD-1) cells	Use before fixation for accurate viability assessment
Necroptosis Antibodies	Anti-MLKL (phospho S358) [94]	Detects activated MLKL in necroptosis	Confirm specificity with RIPK3 inhibition
Pathway Inhibitors	zVAD-FMK (pan-caspase), Nec-1s (RIPK1), GSK'872 (RIPK3) [11] [94]	Pharmacological inhibition of specific death pathways	Use Nec-1s instead of Nec-1 for better specificity; titrate inhibitors for each model
Cell Death Inducers	TNFα, carfilzomib, oxaliplatin [45] [11]	Activate specific cell death pathways	TNFα concentration response reveals threshold effects [45]
Imaging Reagents	CytoVista 3D Clearing Kit [5]	Enhances antibody penetration and image clarity in 3D samples	Critical for organoids >100μm diameter

Technical Considerations for 3D Models

Optimization Guidelines

When applying these assays to 3D organoid cultures, several technical aspects require special attention:

• Antibody Penetration: Thicker spheroids (>100μm) require optimized permeabilization and extended antibody incubation times. Titrate antibodies specifically for your organoid model, testing concentrations from 1:10 to 1:1000 [5].
• Imaging Considerations: Use microscopes with Z-stack capabilities and deconvolution software. Clearing reagents significantly improve image quality in 3D samples [5].
• Appropriate Controls: Include both negative (untreated) and positive (inhibitor-treated) controls. For caspase reporters, verify specificity using caspase-deficient cell lines (e.g., MCF-7 for caspase-3) [11].
• Multiparameter Assessment: Rely on multiple complementary assays rather than a single readout, as cell death pathways can overlap and exhibit context-dependent crosstalk [93] [94].

Data Interpretation Challenges

In organoid models, heterogeneity in cell composition and differentiation states can create subpopulations with different susceptibilities to cell death pathways. The RIP3-caspase3 assay reveals that TNFα stimulation typically shows a preference for RIP1-independent cell death pathways, with apoptosis playing the primary role and necroptosis serving a secondary function [45]. Quantitative analysis should account for this heterogeneity through single-cell resolution approaches rather than bulk measurements alone.

The precise discrimination between apoptosis and necroptosis in 3D organoid cultures requires integrated assessment strategies that combine pathway-specific molecular markers, pharmacological inhibition, and real-time activity monitoring. The protocols outlined here, particularly the RIP3-caspase3 assay and real-time caspase reporters, provide robust frameworks for investigating these cell death pathways in physiologically relevant models. As organoid technology continues to advance, these approaches will be essential for accurate disease modeling, drug screening, and therapeutic development in areas including cancer, inflammatory disorders, and neurodegenerative diseases.

Conclusion

The integration of real-time caspase activity monitoring within 3D organoid models represents a paradigm shift in biomedical research, successfully bridging the gap between conventional in vitro assays and clinical reality. This synthesis of foundational knowledge, advanced methodologies, robust optimization, and rigorous clinical validation establishes organoids as an indispensable platform for drug discovery and personalized medicine. The key takeaway is that caspase dynamics provide a critical, functional readout of treatment efficacy and mechanisms of cell death within a highly physiologically relevant context. Future directions will involve standardizing these complex assays for wider adoption, developing multi-omics integrations for deeper mechanistic insights, and advancing toward prospective clinical trials where organoid caspase responses directly guide patient-specific therapeutic regimens. This approach promises to significantly improve the predictive accuracy of preclinical studies and accelerate the development of more effective, targeted therapies.

References

• 1. Advancements, Strategies, and Challenges in Organoid- ... [https://www.sciencedirect.com/science/article/pii/S2095809925006083]
• 2. Organoids, 3D Organoid Research [https://www.moleculardevices.com/applications/3d-cell-models/organoids]
• 3. Strategies to overcome the limitations of current organoid ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12033597/]
• 4. Tumor organoid-immune co-culture models: exploring a ... [https://www.nature.com/articles/s41420-025-02407-x]
• 5. Staining 3D Cell Cultures for Imaging | Thermo Fisher Scientific - US [https://www.thermofisher.com/us/en/home/references/protocols/cell-and-tissue-analysis/protocols/3d-organoid-staining.html]
• 6. Digitalized organoids: integrated pipeline for high-speed ... [https://www.nature.com/articles/s41592-025-02685-4]
• 7. Apoptosis: A Comprehensive Overview of Signaling Pathways ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11592877/]
• 8. Apoptosis signaling pathways and lymphocyte homeostasis [https://www.nature.com/articles/cr200752]
• 9. Apoptotic signaling cascades [https://www.sciencedirect.com/science/article/abs/pii/S0278584603000162]
• 10. Cell Death Pathways [https://www.cellsignal.com/pathways/by-research-area/cell-death-pathways?srsltid=AfmBOopljRUxNE87rBeogARtgQi_6nh_u2wqolsPQFPrsG4x2CwJi7Z1]
• 11. Integrated real-time imaging of executioner caspase ... [https://www.nature.com/articles/s41420-025-02662-y]
• 12. Integrated real-time imaging of executioner caspase dynamics ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12328661/]
• 13. Caspase-Glo® 3/7 3D Assay [https://www.promega.com/products/cell-health-assays/apoptosis-assays/caspase-glo-3-7-3d-assay/]
• 14. 5 steps to creating 3D cell culture models [https://www.thermofisher.com/us/en/home/life-science/cell-culture/organoids-spheroids-3d-cell-culture/5-steps-creating-3d-cell-models.html]
• 15. Apoptotic Caspases-3 and -7 Cleave Extracellular ... [https://www.mdpi.com/1422-0067/26/8/3466]
• 16. An organoids biobank for recapitulating tumor ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7369175/]
• 17. Organoids as Next-Generation Models for Tumor ... [https://www.mdpi.com/2674-1172/4/4/23]
• 18. Organoid models in oncology: advancing precision cancer ... [https://www.cancerbiomed.org/content/early/2025/07/24/j.issn.2095-3941.2025.0127]
• 19. Subclonal response heterogeneity to define cancer ... [https://www.nature.com/articles/s41598-025-96204-2]
• 20. Protocol for drug screening of patient-derived tumor ... [https://www.sciencedirect.com/science/article/pii/S2666166722002878]
• 21. Organoid models of the tumor microenvironment and their ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8256354/]
• 22. Humanized cerebral organoids-based ischemic stroke ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9958103/]
• 23. Caspases as master regulators of programmed cell death [https://www.nature.com/articles/s12276-025-01470-9]
• 24. caspases drive apoptosis-induced proliferation in tissue ... [https://www.nature.com/articles/cdd201747]
• 25. Caspases: structural and molecular mechanisms and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12052993/]
• 26. Decoding the divide: what distinguishes apoptosis-induced ... [https://biosignaling.biomedcentral.com/articles/10.1186/s12964-025-02336-3]
• 27. Emerging role of immunogenic cell death in cancer ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1390263/full]
• 28. Immunogenic Apoptotic Cell Death and Anticancer Immunity [https://pubmed.ncbi.nlm.nih.gov/27558820/]
• 29. Comparing the effects of different cell death programs in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6294769/]
• 30. The Role of Apoptosis-Induced Proliferation for Regeneration ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3405855/]
• 31. 3D-printed microplate inserts for long term high-resolution ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8015192/]
• 32. Strategies for genetic manipulation of adult stem cell- ... [https://www.nature.com/articles/s12276-021-00609-8]
• 33. Reproducible Drug Screening Assays Using Single ... [https://www.promega.com/resources/pubhub/2023/reproducible-drug-screening-assays-using-single-organoids/]
• 34. Generation of Stable Expression Mammalian Cell Lines ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6261361/]
• 35. Lentiviral Transduction Technology: Principles, ... [https://www.cd-genomics.com/blog/lentiviral-transduction-principles-experimental-steps-applications/]
• 36. Generating Stable Cell Lines with Lentivirus [https://www.addgene.org/protocols/generating-stable-cell-lines/]
• 37. A Comprehensive Exploration of Caspase Detection Methods [https://www.mdpi.com/1422-0067/25/10/5460]
• 38. Protocol for detection of caspases using immunofluorescence [https://www.abcam.com/en-us/technical-resources/protocols/immunofluorescence-protocol-to-detect-caspases]
• 39. Three-Dimensional Culture System: A New Frontier in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12292892/]
• 40. Novel approaches to 3D cancer heterospheroid culture ... [https://www.sciencedirect.com/science/article/pii/S0014482725002009]
• 41. Overcoming Challenges to Detect Apoptosis in 3D Cell ... [https://www.promegaconnections.com/overcoming-challenges-to-detect-apoptosis-in-3d-cell-structures/]
• 42. Live-cell imaging of cell signaling using genetically encoded ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5730511/]
• 43. Caspase Assays | Thermo Fisher Scientific - US [https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-viability-and-regulation/apoptosis/caspase-assays.html]
• 44. Immunogenic cell death after combined treatment with ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1138920/full]
• 45. Exploring cell death mechanisms in spheroid cultures ... [https://www.nature.com/articles/s41598-024-66805-4]
• 46. A fully automated high-throughput workflow for 3D-based ... [https://elifesciences.org/articles/52904]
• 47. Automation of Organoid Cultures: Current Protocols and ... [https://www.sciencedirect.com/science/article/pii/S2472555222067569]
• 48. Hydrogel innovations for 3D organoid culture [https://pubmed.ncbi.nlm.nih.gov/40359965/]
• 49. Reproducible extracellular matrices for tumor organoid culture [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06349-x]
• 50. Hybrid hydrogel–extracellular matrix scaffolds identify ... [https://www.nature.com/articles/s41563-025-02234-6]
• 51. Dynamic hydrogel mechanics in organoid engineering [https://www.sciencedirect.com/science/article/pii/S2452199X2500427X]
• 52. Protein-level batch-effect correction enhances robustness ... [https://www.nature.com/articles/s41467-025-64718-y]
• 53. an animal-free gel to grow organoids [https://www.hubrecht.eu/bacteria-to-the-rescue-again/]
• 54. Artificial Intelligence tool for prediction of ECM mimics ... [https://www.sciencedirect.com/science/article/pii/S2772950825001505]
• 55. Multiscale light-sheet organoid imaging framework [https://www.nature.com/articles/s41467-022-32465-z]
• 56. Microglia-containing neural organoids as brain ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12528120/]
• 57. Human cerebral organoids maintain integrity and viability ... [https://www.sciencedirect.com/science/article/pii/S2949921625000213]
• 58. Overcoming Imaging Barriers in Organoid and Live Cell Analysis [https://lifesciences.danaher.com/us/en/blog/organoid-live-cell-imaging-challenges-solutions.html]
• 59. The Growing Importance of Three-Dimensional Models and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10467068/]
• 60. Deciphering brain organoid heterogeneity by identifying ... [https://www.nature.com/articles/s42003-025-08855-6]
• 61. Penetration in 3D tumor spheroids and explants [https://www.sciencedirect.com/science/article/pii/S0005273618300877]
• 62. Caspase Inhibitor Z-VAD-FMK [https://www.promega.com/products/cell-health-assays/apoptosis-assays/caspase-inhibitor-z_vad_fmk/]
• 63. A long way to go: caspase inhibitors in clinical use [https://www.nature.com/articles/s41419-021-04240-3]
• 64. In vitro evaluation of the anti-apoptotic drug Z-VAD-FMK on ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4615917/]
• 65. A Comprehensive Exploration of Caspase Detection Methods [https://pmc.ncbi.nlm.nih.gov/articles/PMC11121653/]
• 66. 3D imaging analysis on an organoid-based platform guides ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9753992/]
• 67. Use of High-Throughput Automated Microbioreactor System ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6235343/]
• 68. AI-powered high-throughput digital colony picker platform ... [https://www.nature.com/articles/s41467-025-63929-7]
• 69. Real time ex vivo chemosensitivity assay for pancreatic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10503742/]
• 70. Ex vivo explant model of adenoma and colorectal cancer to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9730503/]
• 71. Bioengineered 3D models of human pancreatic cancer ... [https://www.nature.com/articles/s41467-021-25921-9]
• 72. Ex vivo treatment of patient biopsies as a novel method to ... [https://www.nature.com/articles/s41598-017-12222-9]
• 73. Viability Analysis and High-Content Live-Cell Imaging for ... [https://www.mdpi.com/2073-4409/12/10/1377]
• 74. Comparative analysis of patient-derived organoids and ... [https://www.medrxiv.org/content/10.1101/2025.08.10.25333051v1.full-text]
• 75. A human breast cancer-derived xenograft and organoid ... [https://www.nature.com/articles/s43018-022-00337-6]
• 76. Advances in precision oncology using patient-derived ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1670328/full]
• 77. Patient-derived organoids (PDOs) and PDO- ... [https://www.sciencedirect.com/science/article/pii/S2667005422000679]
• 78. Comparative analysis of patient-derived organoids ... - PubMed [https://pubmed.ncbi.nlm.nih.gov/40832408/]
• 79. A fully automated high-throughput workflow for 3D-based ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7609049/]
• 80. Caspase-8 contributes to an immuno-hot ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9835222/]
• 81. Integrated real-time imaging of executioner caspase dynamics... [https://www.nature.com/articles/s41420-025-02662-y?error=cookies_not_supported&code=997d5d12-8110-4bfe-afc4-0e9db0552642]
• 82. Detecting Cleaved Caspase-3 in Apoptotic Cells by Flow ... [https://pubmed.ncbi.nlm.nih.gov/27803251/]
• 83. Interleukin-6-derived cancer-associated fibroblasts activate ... [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.897368/full]
• 84. Inhibiting stromal Class I HDACs curbs pancreatic cancer ... [https://www.nature.com/articles/s41467-023-42178-6]
• 85. Pharmacologic Normalization of Pancreatic Cancer ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8024982/]
• 86. Three-Dimensional Cell Cultures in Drug Discovery and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5448717/]
• 87. intestinal 3 automation using an Automated Cell... D organoid culture [https://www.news-medical.net/whitepaper/20240805/3D-Intestinal-Organoid-Culture-Automation-using-an-Automated-Cell-Culture-System.aspx]
• 88. Patient-derived tumor organoids: a new avenue for ... [https://www.nature.com/articles/s12276-024-01272-5]
• 89. High Expression of Caspase-8 Associated with Improved ... [https://www.mdpi.com/2673-7426/1/1/3]
• 90. Application of immune enhanced organoids in modeling ... [https://www.nature.com/articles/s41598-022-17921-6]
• 91. mutant colorectal cancer via patient-derived organoids [https://jeccr.biomedcentral.com/articles/10.1186/s13046-025-03349-z]
• 92. Improved Drug-Response Prediction Model of APC Mutant ... [https://www.mdpi.com/2072-6694/15/23/5531]
• 93. Necroptosis, pyroptosis and apoptosis: an intricate game of ... [https://www.nature.com/articles/s41423-020-00630-3]
• 94. Studying cell death [https://www.abcam.com/en-us/technical-resources/guides/cell-death-guide/studying-cell-death]